<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id><journal-title-group><journal-title>Frontiers in Cell and Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2296-634X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7018668</article-id><article-id pub-id-type="doi">10.3389/fcell.2020.00055</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cell and Developmental Biology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Haiyu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/897884/overview"/></contrib><contrib contrib-type="author"><name><surname>Rao</surname><given-names>Benchen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/775962/overview"/></contrib><contrib contrib-type="author"><name><surname>Lou</surname><given-names>Jiamin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jianhao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/777563/overview"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Zhenguo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/729323/overview"/></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Guangying</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/775086/overview"/></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Zhigang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/743175/overview"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Zujiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/784477/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Gene Hospital of Henan Province, Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Albena Todorova Dinkova-Kostova, University of Dundee, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Wei-Hsiung Yang, Mercer University, United States; Caroline Saucier, Universit&#x000e9; de Sherbrooke, Canada; Nese Atabey, Dokuz Eylul University, Turkey</p></fn><corresp id="c001">*Correspondence: Zhigang Ren, <email>fccrenzg@zzu.edu.cn</email></corresp><corresp id="c002">Zujiang Yu, <email>johnyuem@zzu.edu.cn</email></corresp><fn fn-type="other" id="fn002"><p><sup>&#x02020;</sup>These authors have contributed equally to this work</p></fn><fn fn-type="other" id="fn004"><p>This article was submitted to Signaling, a section of the journal Frontiers in Cell and Developmental Biology</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>8</volume><elocation-id>55</elocation-id><history><date date-type="received"><day>26</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Wang, Rao, Lou, Li, Liu, Li, Cui, Ren and Yu.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Wang, Rao, Lou, Li, Liu, Li, Cui, Ren and Yu</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, leading to a large global cancer burden. Hepatocyte growth factor (HGF) and its high-affinity receptor, mesenchymal epithelial transition factor (c-Met), are closely related to the onset, progression, and metastasis of multiple tumors. The HGF/c-Met axis is involved in cell proliferation, movement, differentiation, invasion, angiogenesis, and apoptosis by activating multiple downstream signaling pathways. In this review, we focus on the function of the HGF/c-Met axis in HCC. The HGF/c-Met axis promotes the onset, proliferation, invasion, and metastasis of HCC. Moreover, it can serve as a biomarker for diagnosis and prognosis, as well as a therapeutic target for HCC. In addition, it is closely related to drug resistance during HCC treatment.</p></abstract><kwd-group><kwd>hepatocellular carcinoma</kwd><kwd>HGF/c-Met axis</kwd><kwd>function</kwd><kwd>molecule target therapy</kwd><kwd>sorafenib</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">National Major Science and Technology Projects of China<named-content content-type="fundref-id">10.13039/501100013076</named-content></funding-source><award-id rid="cn001">2018ZX10301201-008</award-id></award-group><award-group><funding-source id="cn002">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content></funding-source><award-id rid="cn002">81600506</award-id></award-group><award-group><funding-source id="cn003">National Key Research and Development Program of China Stem Cell and Translational Research<named-content content-type="fundref-id">10.13039/501100013290</named-content></funding-source><award-id rid="cn003">2018YFC2000500</award-id></award-group><award-group><funding-source id="cn004">China Postdoctoral Science Foundation<named-content content-type="fundref-id">10.13039/501100002858</named-content></funding-source><award-id rid="cn004">2017464 and 20182814</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><equation-count count="0"/><ref-count count="164"/><page-count count="15"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth leading cause of cancer-related death in the world (<xref rid="B34" ref-type="bibr">Ferlay et al., 2019</xref>), and its burden is expected to increase in the next few years. The main cause of HCC is chronic liver disease caused by hepatitis virus B and/or C. However, other factors are also related to the occurrence of HCC, including alcohol-related liver disease, obesity, type 2 diabetes, and mellitus-related non-alcoholic fatty liver disease (<xref rid="B31" ref-type="bibr">Dyson et al., 2014</xref>; <xref rid="B141" ref-type="bibr">Williams et al., 2014</xref>). Only about 40% of patients with early-stage or localized HCC are suitable for potentially curative treatments (surgical resection, liver transplantation, and local radiofrequency ablation) and 20% are suitable for transcatheter arterial chemoembolization (TACE) if in an intermediate stage (<xref rid="B43" ref-type="bibr">Giordano and Columbano, 2014</xref>). Due to lack of early effective diagnosis, around 80% patients are diagnosed with advanced HCC. The prognosis of advanced HCC is poor, the median overall survival (OS) time is roughly 1&#x02013;2 months (<xref rid="B110" ref-type="bibr">Ren et al., 2020</xref>) and only systemic therapy can improve survival time.</p><p>Systemic treatments with sorafenib or lenvatinib followed by regorafenib, nivolumab, or ramucirumab have been demonstrated to improve survival (<xref rid="B37" ref-type="bibr">Forner et al., 2018</xref>). Among them, sorafenib [against c- rapidly accelerated fibrosarcoma (c-RAF), b-RAF, vascular endothelial growth factor receptor (VEGFR), c-KIT, and platelet-derived growth factor receptor] (<xref rid="B140" ref-type="bibr">Wilhelm et al., 2006</xref>; <xref rid="B43" ref-type="bibr">Giordano and Columbano, 2014</xref>) was the first drug for first-line treatment of advanced HCC (<xref rid="B89" ref-type="bibr">Marisi et al., 2019</xref>; <xref rid="B99" ref-type="bibr">Musso and Beraza, 2019</xref>), until the appearance of lenvatinib [against VEGFR/rearranged during transfection proto-oncogene (RET)/fibroblast growth factor receptor (FGFR)] (<xref rid="B71" ref-type="bibr">Kudo et al., 2018</xref>). Second-line treatments have also been designed over the past few years, including regorafenib (antiangiogenesis) (<xref rid="B14" ref-type="bibr">Bruix et al., 2017</xref>), nivolumab [against the programed cell death-1 (PD1) immune checkpoint] (<xref rid="B32" ref-type="bibr">El-Khoueiry et al., 2017</xref>), and ramucirumab (against VEGFR2) (<xref rid="B163" ref-type="bibr">Zhu et al., 2019</xref>). For sorafenib used in first-line therapy, results of a randomized, placebo-controlled, phase III clinical trial investigating efficacy of sorafenib in 271 patients with HCC have been reported. The primary endpoint, median OS was 6.5 months for patients with sorafenib and 4.2 months for patients with placebo (<xref rid="B22" ref-type="bibr">Cheng et al., 2009</xref>). Another recent study demonstrated that OS was higher in patients treated with sorafenib (10.7 months) than patients who received the placebo (7.9 months) (<xref rid="B85" ref-type="bibr">Llovet et al., 2008</xref>). However, the survival benefit of sorafenib was disappointing in clinical trials, owing to its low response rate and short effective duration, caused by intrinsic and acquired resistance (<xref rid="B22" ref-type="bibr">Cheng et al., 2009</xref>; <xref rid="B86" ref-type="bibr">Llovet et al., 2015</xref>). Therefore, we need to explore the resistance mechanism of sorafenib and novel treatments against HCC, such as c-Met and downstream signaling pathway inhibitors (<xref rid="B55" ref-type="bibr">Hu et al., 2017</xref>).</p><p>Hepatocyte growth factor (HGF) and its high-affinity receptor, mesenchymal epithelial transition factor (c-Met), are closely related to the onset, progression and metastasis of multiple tumors. The HGF/c-Met axis has a pivotal role in normal liver growth, regeneration, and protection (<xref rid="B43" ref-type="bibr">Giordano and Columbano, 2014</xref>). Inappropriate Met activation promotes the onset, proliferation, invasion, and metastasis of HCC (<xref ref-type="fig" rid="F1">Figure 1</xref>) via canonical or non-canonical pathways to regulate cell proliferation, movement, differentiation, invasion, angiogenesis, and anti-apoptosis. HCC patients with high expression of Met have lower survival time than patients with low or no expression of Met (<xref rid="B9" ref-type="bibr">Boccaccio and Comoglio, 2006</xref>). Moreover, the HGF/c-Met axis is regarded as a tumor aggressiveness and prognosis biomarker of patients with HCC (<xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>). In addition, c-Met plays a critical role in drug resistance (<xref rid="B90" ref-type="bibr">Maroun and Rowlands, 2014</xref>). Therefore, targeting HGF/c-Met axis is one of the most promising therapies for HCC (<xref rid="B154" ref-type="bibr">You et al., 2011</xref>; <xref rid="B40" ref-type="bibr">Gao et al., 2012</xref>, <xref rid="B39" ref-type="bibr">2017</xref>; <xref rid="B46" ref-type="bibr">Goyal et al., 2013</xref>; <xref rid="B47" ref-type="bibr">Graveel et al., 2013</xref>; <xref rid="B43" ref-type="bibr">Giordano and Columbano, 2014</xref>; <xref rid="B8" ref-type="bibr">Blagotinsek and Rozman, 2017</xref>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>The function of the HGF/c-Met in hepatocellular carcinoma (HCC). The aberrant activation of HGF/c-Met axis involves several aspects in HCC, including promoting tumor onset, proliferation, invasion and even inducing drug resistance. Moreover, the HGF/c-Met axis could be used as prognosis and diagnosis biomarker for HCC. Therefore, targeting its mechanism in the formation of HCC, several new therapeutic strategies have been designed to treat patients with HCC.</p></caption><graphic xlink:href="fcell-08-00055-g001"/></fig></sec><sec id="S2"><title>The Hgf/c-Met Axis</title><p>Hepatocyte growth factor was originally discovered in <italic>in vitro</italic> experiments as a hepatocyte mitogen (<xref rid="B100" ref-type="bibr">Nakamura et al., 1984</xref>) for primary hepatocytes that promoted the cell motility of epithelial cells (<xref rid="B123" ref-type="bibr">Stoker et al., 1987</xref>). Subsequently, several studies also revealed other effects, such as intensifying cell motility, angiogenesis, immune response, cell differentiation, and anti-apoptosis (<xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>). Hepatocyte stromal cells or HCC tumor cells can express and release HGF into the tumor microenvironment (<xref rid="B94" ref-type="bibr">Matsumoto et al., 2008</xref>). HGF binds to its specific receptor, c-Met, which is located on the surface of hepatocytes, in a paracrine or autocrine manner. Moreover, the autocrine and paracrine activation of c-Met play an important role in the development and metastasis in HCC (<xref rid="B146" ref-type="bibr">Xie et al., 2001</xref>).</p><p>Originally, in a chemically transformed human osteosarcoma cell line, researchers found the c-Met proto-oncogene and identified it as a fusion gene (<xref rid="B23" ref-type="bibr">Cooper et al., 1984</xref>). It encodes the receptor for the ligand HGF. Several kinds of cells express c-Met, such as epithelial cells, neurons, hepatocytes, and hematopoietic cells (<xref rid="B33" ref-type="bibr">Fasolo et al., 2013</xref>). C-Met is a receptor tyrosine kinase (RTK) that is composed of a disulfide-linked heterodimeric complex. The complex is a transmembrane monomer that has five catalytic tyrosines in a cytoplasmic tail with four distinct hotspots (<xref rid="B5" ref-type="bibr">Basilico et al., 2014</xref>). One of five catalytic tyrosine regulates c-Met negatively (Y1003), while the others (Y1234, Y1235, Y1349, Y1356) (<xref rid="B13" ref-type="bibr">Bradley et al., 2017</xref>) regulate c-Met positively. Y1003 regulates Cbl-mediated Met lysosomal degradation. Activated Y1234 and Y1235 upregulate kinase activity and result in phosphorylation of the docking site residues Y1349 and Y1356, leading to the recruitment of adaptor proteins and signaling molecules.</p><p>Additionally, protein kinase-c activates S985 to degenerate c-Met. Hotspots are the domains of Met responsible for interaction with HGF. For four hotspots, the first hotspot is located on blades 2&#x02013;3 of the semaphoring (SEMA) homology domain &#x003b2;-propeller, the known HGF &#x003b2; chain binging site. The second and third hotspot are known as the HGF &#x003b1; chain, localized on blade five of the SEMA domain and immunoglobulin-plexin-transcription factor (IPT) homology domains 2&#x02013;3, respectively. The fourth hotspot is not previously correlated with the HGF binding site, which is across the plexinsemaphorin-integrin homology domain (PSI)-IPT 1 domains. C-Met, activated by the canonical pathway or the non-canonical pathway is involved in cell proliferation, motility, angiogenesis, invasion, and apoptosis.</p><sec id="S2.SS1"><title>Canonical Mode of c-Met Activation Pattern</title><p>The canonical mode of c-Met activation involves the binding of HGF to c-Met, which induces homodimerization and autophosphorylation of the cytoplasmic domain of c-Met and then triggers downstream signaling pathways, including the mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) (<xref rid="B45" ref-type="bibr">Gonzalez et al., 2017</xref>), phosphatidylinositol 3 kinase (PI3K) (<xref rid="B104" ref-type="bibr">Pascale et al., 2016</xref>), p-38 (<xref rid="B75" ref-type="bibr">Lee et al., 2003</xref>), and the Akt/protein kinase B (PKB) (<xref rid="B161" ref-type="bibr">Zhang et al., 2018c</xref>) pathways (<xref ref-type="fig" rid="F2">Figure 2</xref>). Many studies have shown that these signaling pathways are shared with other RTKs (<xref rid="B24" ref-type="bibr">Corso and Giordano, 2013</xref>). Adaptor proteins involved in these signaling pathways include, growth factor bound protein2 (Grb-2), Grb-2 associated binding protein 1 (Gab1), PI3K, signal transducer and activator of transcription 3 (STAT3), SH2-containing inositol 5-phosphatase 1 (SHIP1), phospholipase C&#x003b3; (PLC&#x003b3;), SH2 domain-containing tyrosine phosphatase 2 (SHP2) (<xref rid="B82" ref-type="bibr">Liu et al., 2018</xref>), and Src homology and collagen homology (Shc) (<xref rid="B114" ref-type="bibr">Saucier et al., 2004</xref>). These proteins induce hepatocarcinogenesis and contain Src-homology 2 (SH2) domains or phosphotyrosine-binding domains and Src homology 3 (SH3) domains (<xref rid="B13" ref-type="bibr">Bradley et al., 2017</xref>; <xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>), and are directly or indirectly bound to c-Met.</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>The illustration of the molecule mechanism of HGF/c-Met downstream signaling pathways and the crosstalk between c-Met and other cell signal transduction pathways. HGF binds to c-Met and induces c-Met homodimerization and autophosphorylation, then activates Gab-1, Grb-2, SHC, and STAT3. Grb2 activates SOS, SOS stimulates RAS and then RAS activates RAF, MEK, and ERK/MAPK. Activated ERK/MAPK can enter into the nucleus and modulate transcription factors to regulate cell behaviors. Activated Gab-1 stimulates AKT, PKB and mTOR to regulate transcription factors. C-Met could also interact with other cell signal transduction pathways such as CD44, EGFR, FAK, and &#x003b2;-catenin to regulate cell behaviors.</p></caption><graphic xlink:href="fcell-08-00055-g002"/></fig></sec><sec id="S2.SS2"><title>Non-canonical Mode of c-Met Activation Pattern</title><p>C-Met can also be inappropriately activated by other pathways. Deregulated Met activation can induce several types of tumors in humans. (I) Des-&#x003b3;-carboxy prothrombin (DCP) is secreted from HCC cells and activates c-Met because it contains two structural regions that are similar to HGF (<xref rid="B125" ref-type="bibr">Suzuki et al., 2005</xref>; <xref rid="B157" ref-type="bibr">Zhang Y.S. et al., 2014</xref>). Due to this similarity, DCP can bind to and activate c-Met. Moreover, DCP is used as a tumor screening and diagnostic biomarker owing to its sensitivity and specificity. (II) C-Met is modulated through crosstalk with different membrane receptors, including epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER), Integrin, &#x003b2;- catenin, cluster of differentiation-44 (CD44), intercellular adhesion molecule-1 (ICAM-1), Plexin B1, VEGF-A, insulin receptor (INSR), FAS, Mucin 1 (MUC1), neuropilin (Nrp)-1 and -2, and focal adhesion kinase (FAK) (<xref ref-type="fig" rid="F2">Figure 2</xref>; <xref rid="B60" ref-type="bibr">Jo et al., 2015</xref>; <xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>). Although this crosstalk is not necessary for cell survival, it is able to better integrate the signals presented in the extracellular environment. Even if the crosstalk is redundant in physiological conditions, these interacting receptors may collaborate with each other in promoting tumorigenesis and/or metastasis and even cause resistance to target drugs in pathologic conditions. (III) C-Met overexpression drives the receptor activation and is induced by a few factors, including hypoxia (<xref rid="B105" ref-type="bibr">Pennacchietti et al., 2003</xref>; <xref rid="B42" ref-type="bibr">Ghiso and Giordano, 2013</xref>), inactivation of tumor suppressor genes, activation of upstream oncogenes and loss of miRNAs (<xref rid="B24" ref-type="bibr">Corso and Giordano, 2013</xref>). (IV) C-Met mutations can activate the receptor, thereby altering substrate specificity or catalytic activity. The identification of germline activating mutations in hereditary papillary renal carcinomas is unequivocal evidence correlating Met with cancer (<xref rid="B118" ref-type="bibr">Schmidt et al., 1999</xref>). (V) C-Met can also be activated by amplification. It has been shown that non-canonical pathways are associated with tumor progression, metastasis (<xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>) and drug resistance (<xref rid="B96" ref-type="bibr">Migliore and Giordano, 2008</xref>; <xref rid="B115" ref-type="bibr">Scagliotti et al., 2013</xref>) in <italic>in vivo</italic> experiments. (VI) Autocrine Met-induced-activation is due to ectopic Met expression in cells yielding HGF, especially in acute myeloid leukemia (<xref rid="B67" ref-type="bibr">Kentsis et al., 2012</xref>). (VII) miRNAs directly degrade messenger RNA or repress translation to regulate gene expression (<xref rid="B38" ref-type="bibr">Friedman et al., 2009</xref>). Deregulated miRNA expression in HCC tissues has been detected. (VIII) Long non-coding RNAs (lncRNAs) could modulate c-Met expression by interacting with miRNAs (<xref rid="B155" ref-type="bibr">Zhang et al., 2019</xref>). (IX) Slug can mediate activation of c-Met in a ligand-independent manner because of increased levels of fibronectin and induced integrin &#x003b1; V function (<xref rid="B18" ref-type="bibr">Chang et al., 2019</xref>).</p><p>The HGF/c-Met axis has an important role in cellular behaviors, such as cell proliferation, migration, survival, morphogenesis and the epithelial&#x02013;mesenchymal transition (EMT) (<xref rid="B126" ref-type="bibr">Taher et al., 2002</xref>; <xref rid="B11" ref-type="bibr">Bouattour et al., 2018</xref>). Moreover, it also is essential for liver formation, growth, regeneration, protection, and angiogenesis during embryonic development and in adulthood after injury (<xref rid="B10" ref-type="bibr">Borowiak et al., 2004</xref>). In HGF and c-Met knockout mice, mice are embryonic lethal due in part to impaired liver formation (<xref rid="B117" ref-type="bibr">Schmidt et al., 1995</xref>). After partial hepatectomy, HGF expression levels increased quickly in rodents (<xref rid="B100" ref-type="bibr">Nakamura et al., 1984</xref>), and mice that conditionally inactivate c-Met in mature hepatocytes show insufficient liver regeneration (<xref rid="B10" ref-type="bibr">Borowiak et al., 2004</xref>). However, the aberrant activation of HGF/c-Met signaling pathways, such as c-Met over-expression, amplification, binding to other ligands or abnormally high HGF levels, leads the initiation and progression of tumors, such as non-small cell lung cancer, HCC, colon cancer, renal caner, and breast cancer (<xref rid="B46" ref-type="bibr">Goyal et al., 2013</xref>; <xref rid="B77" ref-type="bibr">Li J. et al., 2019</xref>). Furthermore, both the canonical and non-canonical signaling pathways require the dimerization and autophosphorylation of c-Met. Therefore, c-Met is the key factor in the HGF/c-Met signaling pathways. C-Met and its downstream signal mediators are promising targets in treating patients with advanced HCC.</p></sec></sec><sec id="S3"><title>The Hgf/c-Met Axis in Hcc</title><p>Numerous <italic>in vivo</italic> and <italic>in vitro</italic> studies have demonstrated that HGF/c-Met play a critical role in the development of various human cancers (renal, lung, liver, breast, colon, thyroid, ovarian, and pancreas). HGF/c-Met signaling pathways are uncontrolled in human cancer via overexpression of HGF or c-Met, gene amplification, mutational activation of c-Met, down-regulation of Met-targeted miRNA, binding to other ligands, autocrine signaling, or abnormally high HGF levels. Deregulated activation of c-Met contributes to a few aspects of tumor progression, such as inducing neoplastic cells to disaggregate from the tumor mass, eroding basement membranes, infiltrating stromal matrices, and finally colonizing new tissues to form metastases (<xref rid="B24" ref-type="bibr">Corso and Giordano, 2013</xref>). Here we mainly discuss the HGF/c-Met axis in HCC.</p><sec id="S3.SS1"><title>Onset</title><p>Chronic liver diseases such as cirrhosis and hepatitis B or C are triggers of HCC (<xref rid="B57" ref-type="bibr">Janevska et al., 2015</xref>). There is a complicated interplay between HCC, chronic liver diseases and c-Met. Liver diseases reduce hepatocytes and increase the need for hepatocyte proliferation, thereby promoting up-regulation of c-Met and/or HGF. The increasing c-Met levels induce hepatocyte proliferation, regeneration, and survival during liver repair and delay the development of liver diseases by repressing chronic inflammation and the progression of fibrosis. Although it is potentially beneficial for liver diseases, increased c-Met activity can initiate, drive or promote the progression of HCC (<xref rid="B11" ref-type="bibr">Bouattour et al., 2018</xref>). Reversely, a knockout of the c-Met increased chemically-mediated HCC initiation but did not affect phenobarbital-induced HCC promotion (<xref rid="B92" ref-type="bibr">Marx-Stoelting et al., 2009</xref>). Moreover, the intact and normal HGF/c-Met signaling is elementary for sustaining normal redox homeostasis and could suppress tumor in the <italic>N</italic>-nitrosodiethylamine-induced HCC (<xref rid="B127" ref-type="bibr">Takami et al., 2007</xref>). Additionally, c-Met may induce VEGF-A expression, which can enhance tumor angiogenesis (<xref rid="B78" ref-type="bibr">Li et al., 2018</xref>; <xref rid="B160" ref-type="bibr">Zhang et al., 2018b</xref>).</p><p>As mentioned above, c-Met is aberrantly activated by gene amplification, overexpression, mutation, binding to other ligands, autocrine signaling or abnormally high HGF levels in cancer. However, according to the study by <xref rid="B129" ref-type="bibr">Takeo et al. (2001)</xref>, Met amplification was at a very low frequency in HCC (one-twentieth). In the study by Kondo, the amplification frequency is 159th (<xref rid="B69" ref-type="bibr">Kondo et al., 2013</xref>). Concerning activating Met kinase domain mutations, Park and Di Renzo and Lee and Aebersold (<xref rid="B103" ref-type="bibr">Park et al., 1999</xref>; <xref rid="B27" ref-type="bibr">Di Renzo et al., 2000</xref>; <xref rid="B74" ref-type="bibr">Lee et al., 2000</xref>; <xref rid="B3" ref-type="bibr">Aebersold et al., 2003</xref>) observed three missense mutations in childhood HCC (K1262R, M12681, T11911, respectively) (<xref rid="B103" ref-type="bibr">Park et al., 1999</xref>). Mutations in the Casitas B-cell lymphoma (Cbl)-binding domain are demonstrated to be oncogenic because binding of Cbl to Y1003 causes Met ubiquitination that is vital to maintenance of physiological Met activation and prevention of continued activation of Met (<xref rid="B1" ref-type="bibr">Abella et al., 2005</xref>; <xref rid="B106" ref-type="bibr">Peschard and Park, 2007</xref>). Under normal conditions, activated Met is rapidly removed from the cell surface by ubiquitination, and then targets the lysosomal degradation chamber. More and more evidence shows that the ubiquitination of RTK is the key to its lysosomal degradation and recruitment of the ubiquitin protein ligase Cbl family is required for ligand-induced degradation of many RTKs. Moreover, the phosphorylation of Y1003 provides a direct docking site for the SH2-like crystal structure of Cbl (TKB) domain of Cbl ubiquitin ligase and is required for ligand-dependent ubiquitination and Met receptor degradation. Therefore, Y1003 mutations in the cbl-binding region can lead to the continued activation of Met and its downstream signaling pathways, and even induce cancer. Furthermore, mutations in the juxtamembrane domain led to tumorigenesis in an <italic>in vitro</italic> trial (<xref rid="B47" ref-type="bibr">Graveel et al., 2013</xref>). Levels of c-Met were higher (or showed overexpression) in 20&#x02013;48% of HCC samples than levels in peritumoral liver tissue (<xref rid="B132" ref-type="bibr">Tavian et al., 2000</xref>). Over-expression of c-Met occurs more often than mutation and amplification. While not all HCC are related to HGF or c-Met overexpression (<xref rid="B159" ref-type="bibr">Zhang et al., 2005</xref>), HCC patients with c-Met overexpression have poor prognosis. The expression of HGF is decreased in HCC, but is increased in peritumoral liver tissue (<xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>). The increased secretion of HGF in the peritumoral liver tissue may be due to the increased release of HGF from hepatic stellate cells to the peritumoral liver tissue. While the decreased secretion of HGF in HCC tissue may be due to the HGF from HCC cells directly bounding to c-Met through autocrine pathway.</p><p>Additionally, microRNAs (miRNAs) and suppressor of cytokine signaling 1 (SOCS1) (<xref rid="B50" ref-type="bibr">Gui et al., 2011</xref>) can control hepatocarcinogenesis by regulating HGF/c-Met. <xref rid="B49" ref-type="bibr">Gui et al. (2015</xref>, <xref rid="B48" ref-type="bibr">2017)</xref> have demonstrated that SOCS1 overexpression can inhibit HCC cells proliferation and migration by attenuating HGF-induced phosphorylation of c-Met, Gab1, and ERK1/2. MiR-181a can inhibit hepatocarcinogenesis through repressing activation of c-Met (<xref rid="B70" ref-type="bibr">Korhan et al., 2014</xref>). Therefore, up-regulation of oncogenic miRNA induces HCC progression.</p><p>In addition to the above, cooperation of the HGF/c-Met pathway with MUCI (<xref rid="B12" ref-type="bibr">Bozkaya et al., 2012</xref>) or &#x003b2;-catenin (<xref rid="B131" ref-type="bibr">Tao et al., 2016</xref>) can induce hepatocarcinogenesis. <xref rid="B108" ref-type="bibr">Qiao et al. (2019)</xref> demonstrated that loss of axis inhibition protein (Axin1) cooperated with c-Met to cause HCC in mice. Similarly, loss of &#x003b2;-Catenin also exacerbated hepatocarcinogenesis driven by Met and oncogenic &#x003b2;-catenin (<xref rid="B80" ref-type="bibr">Liang et al., 2018</xref>).</p><p>A study carried out by Kaposi-Novak has found that a Met-regulated expression signature correlated vascular invasion rate and decreased mean survival time and microvessel density in a subset of human HCC and liver metastases (<xref rid="B63" ref-type="bibr">Kaposi-Novak et al., 2006</xref>). <xref rid="B137" ref-type="bibr">Wang et al. (2001)</xref> did a trial by using human Met transgenic mice to understand how ligand-independent activation of RTKs affects tumorigenesis. It was found that transgenic mice developed HCC, which subsided when the transgene was inhibited, which showed that Met over-expression induced tumorigenesis without HGF. The HGF/c-Met axis can also induce onset of HCC by promoting angiogenesis (<xref rid="B43" ref-type="bibr">Giordano and Columbano, 2014</xref>). In summary, although there are many ways to activate the c-met signaling pathway to induce the occurrence of HCC, c-met expression and activation are indispensable. Therefore, c-met is a therapeutic target that is worthy of research, and there are still many mechanisms of how HGF/c-Met signaling mediates tumorigenesis in HCC that we need to explore.</p></sec><sec id="S3.SS2"><title>Proliferation</title><p>Besides onset, the HGF/c-Met axis is also involved in proliferation of HCC. In 2005, to investigate the effects of c-Met expression on HCC cell growth <xref rid="B159" ref-type="bibr">Zhang et al. (2005)</xref> used an adenovirus-delivered small interfering RNA (siRNA) method to observe the knockdown of c-Met on tumorigenic growth of HCC in <italic>in vitro</italic> and <italic>in vivo</italic> trials In the <italic>in vitro</italic> trial, compared with adenovirus alcohol dehydrogenase (AdH1)-null or mock-infected cells, proliferation of MHCC97-L cells, which had high c-Met expression, were inhibited by adenovirus AdH1-siRNA, and c-Met expression also decreased. The MHCC97-L cells were arrested at G1-G0 phase. In the <italic>in vivo</italic> study, the proliferative indices of adenovirus AdH1-siRNA/Met-injected mouse tumors were lower (23.4%) than the adenovirus AdH1-null injected tumors (69.8%) and mock-injected tumors (72.8%). C-Met expression was obviously reduced by adenovirus AdH1-siRNA/Met injection. In addition, some studies have found lncRNAs can promote HCC cells proliferation, migration, and even invasion. According to the study of Zhang, lncRNA FLVCR1-AS1 sponges miR-513c and increases c-Met expression in HCC cells, which induces HCC progression (<xref rid="B158" ref-type="bibr">Zhang et al., 2018a</xref>). In another study, <xref rid="B155" ref-type="bibr">Zhang et al. (2019)</xref> has demonstrated that lncRNA HULC promotes HCC progression by inhibiting miR-2052 expression and activating c-Met signaling pathway. However, another study found that HGF plays a crucial role in HCC proliferation induced by cancer-associated fibroblasts from HCC (H-CAFs) in <italic>in vitro</italic> and <italic>in vivo</italic> trials (<xref rid="B59" ref-type="bibr">Jia et al., 2013</xref>). Tumor volume growth was consistent with HGF production. Furthermore, the effect of H-CAF conditioned medium on proliferation of HCC cells was significantly reduced by anti-HGF. Therefore, according to these studies, HGF/c-Met can induce proliferation of hepatocellular cells.</p></sec><sec id="S3.SS3"><title>Invasion and Metastasis</title><p>The high lethality of HCC results from primary tumors invading and migrating to other tissues. This process begins with tumors invading blood vessels and subsequently migrating into intrahepatic and extrahepatic tissues. Tumor metastasis is a complicated multistep process and invasion is a major element of this process, which includes damage of basement membranes and proteolysis of the extracellular matrix (ECM) (<xref rid="B81" ref-type="bibr">Liotta and Kohn, 2001</xref>). Several studies have reported that overexpression levels of HGF or c-Met in HCC correlate with incidence of invasion and metastasis and suggest that HGF/c-Met signaling had a crucial role in the invasion and metastasis of HCC cells (<xref rid="B133" ref-type="bibr">Ueki et al., 1997</xref>; <xref rid="B61" ref-type="bibr">Junbo et al., 1999</xref>; <xref rid="B138" ref-type="bibr">Wang et al., 2007</xref>). HGF/c-Met signaling pathways are involved in HCC cell invasion via HGF-induced c-Met phosphorylation, AKT phosphorylation, nuclear factor-&#x003ba;B (NF-&#x003ba;B) activation, and matrix metalloproteinase-9 (MMP-9) expression (<xref rid="B138" ref-type="bibr">Wang et al., 2007</xref>).</p><p>To investigate the invasion and metastasis effect of HGF/c-Met signaling in HCC, Liu and colleagues conducted a study using two different HGF-treated HCC cell lines, Hep3B and HepG2. The Hep3B HCC cell line was p53 deficient and overexpressed c-Met after treatment with HGF. Loss of p53 expression reinforced HGF/c-Met signaling, which promoted invasion and metastasis by upregulating Snail expression (<xref rid="B83" ref-type="bibr">Liu et al., 2016</xref>). <xref rid="B145" ref-type="bibr">Xie et al. (2010)</xref> found that overexpression of c-Met induces cell invasion. Other studies have also reported that peritumoral stromal neutrophils and mesenchymal cells secrete high levels of HGF, which drove high rates of proliferation, invasion and metastasis in HCC by promoting the EMT (<xref rid="B28" ref-type="bibr">Ding et al., 2010</xref>; <xref rid="B52" ref-type="bibr">He et al., 2016</xref>). Moreover, phenotypic analysis validated that mixed-lineage leukemia (MLL), an epigenetic regulator, interacts with HGF/c-Met signaling to induce invasion and metastatic growth of HCC cell lines (<xref rid="B91" ref-type="bibr">Marquardt and Thorgeirsson, 2013</xref>; <xref rid="B128" ref-type="bibr">Takeda et al., 2013</xref>).</p><p>The liver is an organ filled with blood vessels that rely on angiogenesis for cellular regeneration (<xref rid="B139" ref-type="bibr">Whittaker et al., 2010</xref>). Likewise, angiogenesis plays a critical role in tumor growth, invasion and metastasis (<xref rid="B119" ref-type="bibr">Semela and Dufour, 2004</xref>). The angiogenic balance between proangiogenic and antiangiogenic factors maintains normal angiogenesis (<xref rid="B119" ref-type="bibr">Semela and Dufour, 2004</xref>). However, the balance in HCC is disordered due to excessive angiogenic factors that are secreted by tumor cells, endothelial cells and pericytes. Many angiogenic factors, such as VEGF-A, HGF, transforming growth factor (TGF) and epidermal growth factor (EGF) (<xref rid="B36" ref-type="bibr">Folkman, 2003</xref>), demonstrated elevated expression levels in HCC tumors (<xref rid="B93" ref-type="bibr">Mas et al., 2007</xref>), Moreover, these factors induce angiogenesis through a number of mechanisms, one of them is via the HGF/c-Met signaling pathway. Several studies have reported that the HGF/c-Met axis induces angiogenesis and cell growth through interaction with the VEGF and VEGFR pathway and decreasing expression of thrombospondin-1 (<xref rid="B162" ref-type="bibr">Zhang et al., 2003</xref>; <xref rid="B2" ref-type="bibr">Abounader and Laterra, 2005</xref>).</p></sec></sec><sec id="S4"><title>Diagnosis and Prognosis</title><p>Although new treatments have been used in HCC patients and provided possible cures, the long-term survival rate is still poor due to late diagnosis and high recurrence. Therefore, sensitive and specific diagnostic or prognostic biomarkers are urgently needed. Although the HGF/c-Met axis is an emerging study target, the possibility of its use in diagnosis and prognosis has been studied in addition to its mechanism in HCC.</p><p>In the study by <xref rid="B148" ref-type="bibr">Yamagamim et al. (2002)</xref>, HCC patients had significantly increased serum levels of HGF than patients with chronic viral hepatitis C and cirrhosis. Thus, the serum HGF concentration may be helpful as a tumor biomarker for HCC. Likewise, <xref rid="B64" ref-type="bibr">Karabulut et al. (2014)</xref> and <xref rid="B164" ref-type="bibr">Zhuang et al. (2017)</xref> also identified serum HGF level as a potential diagnostic. However, <xref rid="B134" ref-type="bibr">Unic et al. (2018)</xref> demonstrated that the individual diagnostic performance of HGF was inadequate. Although the concentration of HGF is obviously higher in patients with alcoholic liver cirrhosis than in healthy humans, there is no significant difference in HGF serum level between cirrhosis patients with HCC and cirrhosis patients without HCC. It may be due to the reduction of hepatocytes in cirrhosis patient, which promotes the secretion of HGF and then activates c-Met to increase hepatocytes proliferation. Moreover, the diagnosis sensitivity of HGF was very high (90.62%) but the specificity was very low (25.81%). In conclusion, although the independent use of HGF for diagnosis is controversial, HGF is useful when combined with other diagnostic markers.</p><p>Some studies also suggested that the HGF/c-Met axis has prognostic value for patients with HCC (<xref rid="B164" ref-type="bibr">Zhuang et al., 2017</xref>; <xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>). Overexpression of c-Met correlated with decreased 5-year survival in patients with HCC. In addition, the Met-driven expression signature defines a subset of HCC which has poor prognosis and an aggressive phenotype (<xref rid="B63" ref-type="bibr">Kaposi-Novak et al., 2006</xref>). <xref rid="B135" ref-type="bibr">Vejchapipat et al. (2004)</xref> has found that inoperable patients with HCC had higher levels of serum HGF than healthy humans due to the impaired clearance of HGF. Serum HGF concentration was negatively correlated with long-term survival time in HCC patients. Additionally, a serum HGF level of 1.0 ng/mL or more indicated a serious prognosis in patients with HCC. Nevertheless, another study (<xref rid="B66" ref-type="bibr">Ke et al., 2009</xref>) showed that c-Met was not an independent prognostic factor of HCC for OS and cumulative recurrence, but the combination of c-Met/CD151 was. Meanwhile, an other study (<xref rid="B44" ref-type="bibr">Gong et al., 2018</xref>) also suggested that the prognostic value of c-Met is contradictory. By univariate analysis, c-Met overexpression was significantly correlated with clinicopathological factors, but not with multivariate analysis. Furthermore, c-Met overexpression was not identified to be obviously correlated with OS rates in this study. The reason for the difference in these studies may be the small number of surveyed people or the different technique and scoring system. Thus, the role of HGF and c-Met as prognostic factors for HCC needs to be explored further in the future. Though, the combination of HGF and c-Met with other biomarkers may be useful in predicting the prognosis of HCC.</p></sec><sec id="S5"><title>Target Therapies</title><p>As mentioned above, there are five therapies that can prolong the expected lifespan of patients with HCC including, surgical resection, liver transplantation, local ablation, TACE and sorafenib. Only 40% percent of patients with early stage HCC are eligible for potentially curative treatments (surgical resection, transplantation, local ablation), which prolong median survival times over 60 months (<xref rid="B86" ref-type="bibr">Llovet et al., 2015</xref>). For patients with intermediate-stage HCC, TACE can improve estimated median survival by 26 months (<xref rid="B72" ref-type="bibr">Kudo et al., 2014</xref>). However, a large proportion of HCC patients are diagnosed at advanced stage and only systemic treatment with sorafenib can extend OS from 6 to 11 months (<xref rid="B85" ref-type="bibr">Llovet et al., 2008</xref>). Thus, sorafenib is regarded as the first-line treatment in advanced HCC patients with a manageable adverse event (<xref rid="B85" ref-type="bibr">Llovet et al., 2008</xref>). Nevertheless, in the past few years, seven randomized phase III clinical trials, which tested other first-line and second-line treatments, in intermediate-stage or advanced-stage HCC patients have not found any obvious OS benefits (<xref rid="B86" ref-type="bibr">Llovet et al., 2015</xref>). Moreover, the intrinsic or acquired resistance of sorafenib is the major obstacle in treatment. Thus, based on the understanding of the role of the HGF/c-Met signaling pathway and the uniqueness of c-Met in HCC, more and more therapeutic strategies target c-Met and the interaction between c-Met and downstream signaling mediators instead of the interaction between HGF and c-Met because of the varying activation of c-Met.</p><sec id="S5.SS1"><title>c-Met Inhibitors</title><p>So far, there are six Met inhibitors developed and they have been tested in 10 HCC clinical trials (<xref rid="B11" ref-type="bibr">Bouattour et al., 2018</xref>). Small molecular kinase inhibitors can block phosphorylation of the catalytic domain in the receptor by competitive or non-competitive antagonism of the ATP binding site, thereby preventing the recruitment of signal transducers and mediators, and thus impeding the transmission of downstream signals (<xref rid="B97" ref-type="bibr">Munshi et al., 2010</xref>; <xref rid="B40" ref-type="bibr">Gao et al., 2012</xref>). Anti-c-Met agents can be categorized into three types: selective c-Met tyrosine kinase inhibitors (TKIs), multi-targeted TKIs including against c-Met, and monoclonal antibodies against HGF or c-Met (<xref rid="B46" ref-type="bibr">Goyal et al., 2013</xref>). A lot of preclinical studies have demonstrated the feasibility of HGF/c-Met as targets for the treatment of patients with HCC. For instance, AMG 337, a potential and highly selective small molecule Met kinase inhibitor, significantly decreases tumor growth of Met-high-expression and Met-amplified HCC cell lines in <italic>in vitro</italic> and <italic>in vivo</italic> trials (<xref rid="B30" ref-type="bibr">Du et al., 2016</xref>). Additionally, Indo5, selectively abrogating HGF-induced c-Met pathway activation and brain-derived neurotrophic factor (BDNF)/nerve growth factor (NDF)-induced Trks signaling activation, significantly inhibits HCC tumor growth in xenograft mice (<xref rid="B87" ref-type="bibr">Luo et al., 2019</xref>). Moreover, PHA665752 supressed cell proliferation, and induced apoptosis in MHCC97-L and MHCC97-H cells which overexpress c-Met through blocking phosphorylation of c-Met and downstream PI3K/Akt and MAPK/Erk pathways (<xref rid="B154" ref-type="bibr">You et al., 2011</xref>). PHA665752 also repressed MHCC97-L and MHCC97-H tumor growth in xenograft models.</p><p>Also, several clinical trials are (<xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>) being carried out in HCC patients using c-Met inhibitors (<xref rid="T1" ref-type="table">Table 1</xref>), including cabozanitinib, foretinib, cobazitinib, gefitinib, crizotinib, MSC2156119, AZD4547, MK2461, and INC280 (<xref rid="B116" ref-type="bibr">Schiffer et al., 2005</xref>; <xref rid="B46" ref-type="bibr">Goyal et al., 2013</xref>; <xref rid="B7" ref-type="bibr">Bladt et al., 2014</xref>; <xref rid="B124" ref-type="bibr">Sun et al., 2017</xref>; <xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>). Among them, cabozanitinib is undergoing randomized phase III clinical trials. In the latest clinical trial, OS and progression-free survival (PFS) in months was calculated for Phase 2 of Tepotinib 500 mg (5.55 and 3.22 months, respectively) (NCT02115373). In a randomized phase II study of axitinib, axitinib combined with best supportive care (BSC) did not improve OS versus placebo combined with BSC (<xref rid="B62" ref-type="bibr">Kang et al., 2015</xref>) (NCT01210495). Nevertheless, axitinib combined with BSC led to a significant prolongation of PFS and time to tumor progression (TTP) and an increase of clinical benefit rate (CBR), and the toxicity of patients with advanced HCC is acceptable.</p><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>Drugs targeting HGF/c-Met in hepatocellular carcinoma patients.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Drug</td><td valign="top" align="left" rowspan="1" colspan="1">Target</td><td valign="top" align="center" rowspan="1" colspan="1">Phase</td><td valign="top" align="left" rowspan="1" colspan="1">Activity</td><td valign="top" align="left" rowspan="1" colspan="1">Type</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Tivantinib</td><td valign="top" align="left" rowspan="1" colspan="1">c-Met, tubulin</td><td valign="top" align="center" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">Failed</td><td valign="top" align="left" rowspan="1" colspan="1">Non-selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crizotinib</td><td valign="top" align="left" rowspan="1" colspan="1">Met, ALK, ROS1</td><td valign="top" align="center" rowspan="1" colspan="1">Ib</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-angiogenesis</td><td valign="top" align="left" rowspan="1" colspan="1">Non-selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cabozantinib</td><td valign="top" align="left" rowspan="1" colspan="1">c-Met, KDR, RET, KIT, TIE-2, FLT-3</td><td valign="top" align="center" rowspan="1" colspan="1">III</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">Non-selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Foretinib</td><td valign="top" align="left" rowspan="1" colspan="1">Met, VEGFR2, KIT, FLT-3, PDGFR &#x003b2;, TIE-2</td><td valign="top" align="center" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">Non-selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cobazitinib</td><td valign="top" align="left" rowspan="1" colspan="1">c-Met, VEGFR-2, RET</td><td valign="top" align="center" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">Non-selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MSC2156119J</td><td valign="top" align="left" rowspan="1" colspan="1">c-Met</td><td valign="top" align="center" rowspan="1" colspan="1">Ib/II</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor, Anti-metastasis</td><td valign="top" align="left" rowspan="1" colspan="1">Selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gefitinib</td><td valign="top" align="left" rowspan="1" colspan="1">EGFR, c-Met, HGF</td><td valign="top" align="center" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">Non-selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK2461</td><td valign="top" align="left" rowspan="1" colspan="1">c-Met, Ftl-1</td><td valign="top" align="center" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">Non-selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Capmatinib</td><td valign="top" align="left" rowspan="1" colspan="1">c-Met</td><td valign="top" align="center" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">Selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tepotinib</td><td valign="top" align="left" rowspan="1" colspan="1">c-Met</td><td valign="top" align="center" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">Selective TKI</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Golvatinib</td><td valign="top" align="left" rowspan="1" colspan="1">c-Met, KDR</td><td valign="top" align="center" rowspan="1" colspan="1">II</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">Non-selective TKI</td></tr></tbody></table></table-wrap><p>However, there is currently no effective method for treating HCC based on traditional monotherapy with TKIs. In a previous phase II randomized controlled clinical study, Tivantinib, a highly selective c-Met inhibitor, improved median time to progression and OS time in patients with Met-high advanced HCC compared with placebo (<xref rid="B113" ref-type="bibr">Santoro et al., 2013</xref>). However, in a randomized phase III double-blind clinical trial, tivantinib did not improve OS time in patients with Met-high advanced HCC treated with sorafenib compared with placebo (<xref rid="B111" ref-type="bibr">Rimassa et al., 2018</xref>) (NCT01755767). Despite the failure of tivantinib in a phase III clinical trial to achieve its primary endpoint, we could not deny the role of c-Met inhibitors in the treatment of liver cancer. The reason for this failure, in my opinion, may be due to tivantinib being a non-selective c-Met inhibitor rather a selective c-Met inhibitor. The cytotoxicity against many HCC cell lines of tivantinib was unrelated to c-Met expression but related to inhibiting microtubule assembly (<xref rid="B4" ref-type="bibr">Aoyama et al., 2014</xref>) and Glycogen Synthase Kinase-3 alpha (GSK3a) and beta (GSK3b) (<xref rid="B109" ref-type="bibr">Remsing Rix et al., 2014</xref>) in other studies. Inhibition of non-c-Met targets may enhance the antitumor activity of non-selective c-Met inhibitors, but is also correlated with increased toxicity and limits the dose so that inhibitors cannot effectively suppress c-Met (<xref rid="B11" ref-type="bibr">Bouattour et al., 2018</xref>). Furthermore, the increased toxicity and limitation of potential benefit may outweigh the enhanced antitumor activity because of inhibition of multiple targets. Moreover, we cannot attribute the anti-tumor effect of non-selective c-Met inhibitors to the inhibition of c-Met. Thus, selective c-Met inhibitors may be a better choice for treatment in patients and more studies are needed to identify the reason for phase II clinical trial failure and the feasibility of using c-Met targeting therapies.</p></sec><sec id="S5.SS2"><title>MicroRNAs</title><p>Fortunately, using potential miRNAs for suppressing aberrant c-Met signal is an emerging and promising therapy strategy that bypasses traditional approaches (<xref rid="B65" ref-type="bibr">Karagonlar et al., 2015</xref>) (<xref rid="T2" ref-type="table">Table 2</xref>). miRNAs are small non-coding RNAs and regulate gene expression by resolving mRNA or suppressing translation (<xref rid="B65" ref-type="bibr">Karagonlar et al., 2015</xref>). Previous studies have found that miRNA expression in cancer tissue is different from normal tissues (<xref rid="B98" ref-type="bibr">Murakami et al., 2006</xref>; <xref rid="B136" ref-type="bibr">Volinia et al., 2006</xref>; <xref rid="B73" ref-type="bibr">Ladeiro et al., 2008</xref>). miRNAs can not only inhibit tumor growth, proliferation, invasion, and metastasis but also induce many kinds of tumors. Herein, we mainly focus on the role of miRNAs in HCC. For example, miR-101 suppresses the proliferation and migration of HCC cells and tumors through targeting HGF/c-Met, Girdin, SOX9 and TGF-&#x003b2; in <italic>in vitro</italic> and <italic>in vivo</italic> trials (<xref rid="B17" ref-type="bibr">Cao et al., 2016</xref>; <xref rid="B150" ref-type="bibr">Yang et al., 2016</xref>; <xref rid="B149" ref-type="bibr">Yan et al., 2018</xref>; <xref rid="B84" ref-type="bibr">Liu et al., 2019</xref>). miRNA-206 targets c-Met and cyclin-dependent kinase 6 (Cdk6) to suppress development of HCC in mice (<xref rid="B142" ref-type="bibr">Wu et al., 2017</xref>). Also, miR-26a inhibits tumor growth, metastasis and angiogenesis of HCC via targeting HGF-induced c-Met signaling pathways and FBXO11, ST3GAL5 signaling pathways (<xref rid="B151" ref-type="bibr">Yang et al., 2014</xref>; <xref rid="B16" ref-type="bibr">Cai et al., 2017</xref>; <xref rid="B88" ref-type="bibr">Ma et al., 2018</xref>). MiR-93 induces HCC cell proliferation and invasion by activating c-Met/PI3K/Akt signaling pathways and targeting PDCD4 and TIMP2 (<xref rid="B101" ref-type="bibr">Ohta et al., 2015</xref>; <xref rid="B58" ref-type="bibr">Ji et al., 2017</xref>; <xref rid="B147" ref-type="bibr">Xue et al., 2018</xref>). Thus, we can design miRNA mimics to overexpress miRNAs that down-regulate c-Met signaling pathways, and design miRNAs antagonists to inhibit miRNAs that up-regulate c-Met signaling pathways (<xref rid="B65" ref-type="bibr">Karagonlar et al., 2015</xref>). Moreover, one of the major advantages of miRNA therapy is simultaneously targeting multiple effectors in several signaling pathways involved in tumorigenesis.</p><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>miRNAs that target HGF/c-Met signaling in hepatocellular carcinoma.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">miRNAs</td><td valign="top" align="left" rowspan="1" colspan="1">Functions</td><td valign="top" align="left" rowspan="1" colspan="1">Mechanisms</td><td valign="top" align="left" rowspan="1" colspan="1">References</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-34</td><td valign="top" align="left" rowspan="1" colspan="1">Represses cell invasion, proliferation, migration promotes apoptosis</td><td valign="top" align="left" rowspan="1" colspan="1">Upregulation of p53 Repression of c-Met Cooperation with p53 to repress c-Met</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B26" ref-type="bibr">Dang et al., 2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-181a</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits cell motility and invasion</td><td valign="top" align="left" rowspan="1" colspan="1">Inhabitation of c-Met</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B70" ref-type="bibr">Korhan et al., 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-122</td><td valign="top" align="left" rowspan="1" colspan="1">Induces apoptosis</td><td valign="top" align="left" rowspan="1" colspan="1">Inhabitation of c-Met</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B152" ref-type="bibr">Yang et al., 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-199</td><td valign="top" align="left" rowspan="1" colspan="1">Represses cell motility, invasion, proliferation</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of c-Met downstream signaling Repression of CD44 and STAT3</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B23" ref-type="bibr">Cooper et al., 1984</xref>; <xref rid="B53" ref-type="bibr">Henry et al., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-26a</td><td valign="top" align="left" rowspan="1" colspan="1">anti-angiogenesis</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of angiogenesis by suppressing VEGF-A and HGF Inhibition of c-Met downstream signaling Suppression of FBXO11 and ST3GAL5 signaling pathways</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B151" ref-type="bibr">Yang et al., 2014</xref>; <xref rid="B16" ref-type="bibr">Cai et al., 2017</xref>; <xref rid="B88" ref-type="bibr">Ma et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-148a</td><td valign="top" align="left" rowspan="1" colspan="1">Promotes apoptosis, Suppress cell invasion</td><td valign="top" align="left" rowspan="1" colspan="1">Suppression of EMT by targeting c-Met/SNAIL signaling</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B156" ref-type="bibr">Zhang J.P. et al., 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-198</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits cell migration, invasion</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of c-Met</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B130" ref-type="bibr">Tan et al., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-449</td><td valign="top" align="left" rowspan="1" colspan="1">Represses cell migration, invasion Promotes apoptosis, Reduces proliferation</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of c-Met</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B15" ref-type="bibr">Buurman et al., 2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-93</td><td valign="top" align="left" rowspan="1" colspan="1">Promotes cell proliferation, migration, invasion represses apoptosis</td><td valign="top" align="left" rowspan="1" colspan="1">Activation of c-Met/P13K/AKT pathway Suppression of PTEN and CDKN1A Inhibition of PDCD4 and TIMP2</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B101" ref-type="bibr">Ohta et al., 2015</xref>; <xref rid="B58" ref-type="bibr">Ji et al., 2017</xref>; <xref rid="B147" ref-type="bibr">Xue et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-101</td><td valign="top" align="left" rowspan="1" colspan="1">Suppresses cell migration, proliferation</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of c-Met Suppression of Girdin, SOX9, and TGF-&#x003b2;</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B17" ref-type="bibr">Cao et al., 2016</xref>; <xref rid="B150" ref-type="bibr">Yang et al., 2016</xref>; <xref rid="B149" ref-type="bibr">Yan et al., 2018</xref>; <xref rid="B84" ref-type="bibr">Liu et al., 2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">miR-206</td><td valign="top" align="left" rowspan="1" colspan="1">Suppresses proliferation, Induces apoptosis</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of c-Met</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B142" ref-type="bibr">Wu et al., 2017</xref></td></tr></tbody></table></table-wrap></sec><sec id="S5.SS3"><title>Side Effect of c-Met Inhibitors</title><p>Although c-Met inhibitors show a survival benefit for advanced HCC, there has also been some toxicity and adverse effects demonstrated. For instance, compound 8 was a potent and highly selective ATP competitive c-Met inhibitor. Moreover, compound 8 showed good oral bioavailability and good half life and moderate plasma clearance and volume distribution. In addition, Compound 8 also demonstrated effective tumor inhibition. However, it increased heart rate, cardiac output, and induced myocardial degeneration in mice and thus was terminated as a preclinical candidate (<xref rid="B25" ref-type="bibr">Cui et al., 2013</xref>). Also, adverse effects such as hypertension, decreased appetite, ascites and pyrexia were found in a phase I/II multicenter study of the single-agent foretinib (<xref rid="B153" ref-type="bibr">Yau et al., 2017</xref>). Additionally, ascites, anemia, abdominal pain, and neutropenia were observed in a phase III study of tivantinib (<xref rid="B111" ref-type="bibr">Rimassa et al., 2018</xref>). The reason for these aforementioned side effects may be correlated with the physiological function of HGF/c-Met in many organs, including cytoprotective, regenerative, and reduction of apoptosis after injury (<xref rid="B6" ref-type="bibr">Birchmeier et al., 2003</xref>). Thus, c-Met inhibitors may block the physiological function of HGF/c-Met and induce side effects. Moreover, the adverse effect of c-Met inhibitors may be due to the inhibition of non-c-Met targets when using non-selective c-Met inhibitors.</p></sec><sec id="S5.SS4"><title>Inhibitors of c-Met Downstream Mediators</title><p>To solve the side effects mentioned above, several therapy strategies have been suggested. Among them, specifically targeting the downstream mediators of c-Met involved in tumor progression is a promising method, including the Grb2 SH2 domain, Src, MAPK, STAT3, Shp2 (<xref rid="B82" ref-type="bibr">Liu et al., 2018</xref>), and Fak (<xref rid="B60" ref-type="bibr">Jo et al., 2015</xref>). Nevertheless, there are still problems, especially because these signal pathways are shared with other RTKs, which may cause other unpredictable reactions. Therefore, this requires the identification of more specific and suitable downstream targets.</p><p>Recently endosomal processing has been demonstrated to play a pivotal role in the progression of HCC (<xref rid="B54" ref-type="bibr">Hu et al., 2015</xref>). Receptor endocytosis is crucial for signal transduction, either clathrin-dependent or &#x02013;independent (<xref rid="B121" ref-type="bibr">Sorkin and von Zastrow, 2009</xref>; <xref rid="B95" ref-type="bibr">McMahon and Boucrot, 2011</xref>). HGF binding to c-Met induces the activation of downstream signal mediators, including ERK (<xref rid="B154" ref-type="bibr">You et al., 2011</xref>), c-Jun N-terminal kinase (JNK) (<xref rid="B112" ref-type="bibr">Rodrigues et al., 1997</xref>) and AKT (<xref rid="B161" ref-type="bibr">Zhang et al., 2018c</xref>). Both JNK and ERK mediate HCC cell migration by phosphorylating paxillin at serine residues, which is called an HGF-induced focal adhesion signaling molecule (<xref rid="B54" ref-type="bibr">Hu et al., 2015</xref>). Protein kinases C &#x003b5; (PKC&#x003b5;) and golgi-localized &#x003b3;-ear-containing ARF binding protein 3 (GGA3) regulate HGF-induced c-Met endocytosis (<xref rid="B68" ref-type="bibr">Kermorgant et al., 2004</xref>) to direct fluctuating JNK and paxillin signaling pathways which involve HCC cell migration (<xref rid="B54" ref-type="bibr">Hu et al., 2015</xref>). Importantly, endocytosis blockers, such as dynasore, could prevent the HGF-induced HCC cell migration and invasion by inhibiting critical endosomal components (<xref rid="B54" ref-type="bibr">Hu et al., 2015</xref>). Thus, critical endosomal components may be promising targets in HGF/c-Met signaling pathways for HCC treatment. In addition, <xref rid="B55" ref-type="bibr">Hu et al. (2017)</xref> suggested that hydrogen peroxide-inducible clone-5 (Hic-5) may be crucial for c-Met signaling pathways and HCC metastasis because it mediates HGF-induced reactive oxygen species (ROS)-JNK-signaling pathways in HCC (<xref rid="B143" ref-type="bibr">Wu et al., 2015</xref>) and may be also a specific and safe target for treating HCC patients.</p></sec><sec id="S5.SS5"><title>Natural Compound and Herbal Medicines</title><p>In recent years, more and more studies have found that natural compounds can inhibit the progression of liver cancer. For example, deguelin can suppress tumor angiogenesis on vascular endothelial cells by decreasing autocrine VEGF and repressing HGF-induced c-Met signaling pathways, thereby inhibiting HCC progression (<xref rid="B78" ref-type="bibr">Li et al., 2018</xref>). Also, Cinobufacini, a well-known traditional Chinese medicine extracted from toad skins and venom glands, has a therapeutic effect in HCC (<xref rid="B107" ref-type="bibr">Qi et al., 2018</xref>). A study has found that Cinobufacini could suppress HepG2 cell invasion and metastasis through the inhibition of the c-Met/ERK induced EMT (<xref rid="B107" ref-type="bibr">Qi et al., 2018</xref>). Moreover, madecassoside (MAD), isolated from <italic>Centella asiatica</italic> (<xref rid="B79" ref-type="bibr">Li et al., 2016</xref>) could repress the activation of the HGF-induced c-Met-PKC-ERK1/2-Cyclooxygenase-2 (COX-2)-Prostaglandin E2 (PGE2) cascade to inhibit HCC cell proliferation and invasion. In conclusion, natural compounds and herbals may be potential therapeutic targets for HCC.</p></sec><sec id="S5.SS6"><title>Resistance in c-Met Inhibitors and Sorafenib and Combined Inhibition of HGF/c-Met and Other Pathways</title><p>C-Met inhibitor therapy has failed to result in satisfactory outcomes in phase III clinical trials for HCC. Therefore, it is urgent to understand mechanisms and find new strategies such as effective combination therapies. Several studies have shown resistance in c-Met inhibitors due to various mechanisms. First, c-Met inhibitors only affect high-expression c-Met patients with HCC. Thus, enrolled low-expression c-Met patients with HCC could lead to the occurrence of resistance in c-Met inhibitors. Second, as mentioned above, c-Met inhibitors which target the interaction between HGF and c-Met may lose efficacy owing to cell attachment (<xref rid="B137" ref-type="bibr">Wang et al., 2001</xref>), gene amplification of c-Met, DCP binding to c-Met (<xref rid="B125" ref-type="bibr">Suzuki et al., 2005</xref>), gene mutation in the c-Met activation loop (<xref rid="B102" ref-type="bibr">Okuma and Kondo, 2016</xref>) and crosstalk with other membrane receptors (<xref rid="B41" ref-type="bibr">Garcia-Vilas and Medina, 2018</xref>). Third, inhibition of c-Met signaling pathways triggers the EGFR pathway as a compensatory survival pathway (<xref rid="B122" ref-type="bibr">Steinway et al., 2015</xref>). Fourth, phosphorylation status of FGFR determines different sensitivities of HCC cells to c-Met inhibitors (<xref rid="B60" ref-type="bibr">Jo et al., 2015</xref>). Fifth, <xref rid="B76" ref-type="bibr">Li H. et al. (2019)</xref> suggested that c-Met inhibitors up-regulate the expression of PD-L1 in HCC cells by suppressing GSK3B-mediated PD-L1 degradation and induce T-cell suppression and tumor evasion of the immune response. Finally, when inhibiting the activation of HGF-induced c-Met, HCC cells can sustain survival through Y1234/1235-dephosphorylated c-Met induced autophagy (<xref rid="B56" ref-type="bibr">Huang et al., 2019</xref>).</p><p>New therapeutic strategies have been developed against the mechanism of c-Met inhibitors resistance described above. Among them, combined c-Met inhibitors and other pathway inhibitors is a promising treatment. For example, combined inhibition of both c-Met and EGFR pathways could repress the tumor growth of HCC (<xref rid="B122" ref-type="bibr">Steinway et al., 2015</xref>). Additionally, targeting both c-Met and FGFR pathways provides superior suppression of HCC progression (<xref rid="B60" ref-type="bibr">Jo et al., 2015</xref>). Also, combination of c-Met inhibitor and anti-PD1 treatment represses HCC growth and improves mouse survival (<xref rid="B76" ref-type="bibr">Li H. et al., 2019</xref>). Moreover, targeting c-Met and autophagy could overcome resistance in HCC (<xref rid="B56" ref-type="bibr">Huang et al., 2019</xref>).</p><p>Recently, a growing body of evidence suggests that aberrant activation of HGF/c-Met signaling is associated with resistance of target therapies (<xref rid="B24" ref-type="bibr">Corso and Giordano, 2013</xref>), including sorafenib. Sorafenib is a standard therapy for advanced HCC, thus the resistance to sorafenib is a major concerning problem. <xref rid="B35" ref-type="bibr">Firtina Karagonlar et al. (2016)</xref> have found that in HCC patients on long term sorafenib treatment, the upregulation of HGF induces autocrine activation of HGF/c-Met signaling pathways, increasing the invasion and migration abilities of HCC cells and leading to resistance to sorafenib. Moreover, a recent study has demonstrated that tumor associated M2 macrophages secret HGF in a feed-forward manner, leading the resistance to sorafenib (<xref rid="B29" ref-type="bibr">Dong et al., 2019</xref>). Also, a new study found that HGF activates phosphorylated (P)-ERK/Snail/EMT, P-STAT3/Snail/EMT (<xref rid="B21" ref-type="bibr">Chen et al., 2019</xref>) and AKT/ERK1/2-EGR1 (<xref rid="B51" ref-type="bibr">Han et al., 2017</xref>; <xref rid="B20" ref-type="bibr">Chen and Xia, 2019</xref>; <xref rid="B144" ref-type="bibr">Xiang et al., 2019</xref>) signaling pathways to induce the resistance to sorafenib. According to the study of Chen, IncRNA NEAT1 induces sorafenib resistance of HCC patients through repressing miR-335 expression and activation of c-Met-Akt signaling pathway (<xref rid="B20" ref-type="bibr">Chen and Xia, 2019</xref>). Thus, the concentration of HGF in serum may be a potential predictive marker for sorafenib efficacy (<xref rid="B120" ref-type="bibr">Shao et al., 2015</xref>) and the combination of HGF and c-Met inhibitors and sorefenib could improve the efficacy of the first line systemic treatment (<xref rid="B46" ref-type="bibr">Goyal et al., 2013</xref>; <xref rid="B29" ref-type="bibr">Dong et al., 2019</xref>). For instance, regorafenib plays a crucial role of reversing HGF-induced sorafenib resistance through the inhibition of the EMT (<xref rid="B19" ref-type="bibr">Chen et al., 2016</xref>, <xref rid="B21" ref-type="bibr">2019</xref>). Angiopoietin-like protein (ANGPTL1) not only inhibits sorafenib resistance, but also inhibits cancer stemness and tumor growth of HCC cells via suppressing the EMT through the Met-AKT/ERK-EGR-1-Slug signaling cascade (<xref rid="B19" ref-type="bibr">Chen et al., 2016</xref>).</p><p>In conclusion, although the tivantinib phase III trial failed and the reason is not clear, the role of c-Met inhibitors in treating HCC can not be denied. C-Met inhibitors are still mainstream of research and deserve more research on its cause of failure and new clinical trials. miRNAs, natural compound and herbal medicines are emerging treatments of HCC which can inhibit multiple pathways including c-Met signaling pathway. But it also means that there may be other side effects. The advantage of c-met downstream pathway inhibitors is that they are highly targeted and have little side effects, but this requires us to further understand the key targets of HCC. The drug resistance may be due to the heterogeneity of liver cancer cells and combination therapy may be a good solution.</p></sec></sec><sec id="S6"><title>Conclusion</title><p>The HGF/c-Met axis has an important role in cellular behaviors such as cell proliferation, migration, survival, migration, morphogenesis, and the EMT. Moreover, it is also essential for liver formation, growth, regeneration and protection and angiogenesis during embryonic development and in adulthood after injury. Especially in chronic liver diseases, inflammation decreases hepatocytes and increases the need for c-Met activity to promote hepatocyte proliferation, regeneration and suppress inflammation. Nevertheless, the aberrant activation of c-Met and downstream signaling pathways through overexpression of HGF or c-Met, gene amplification, mutational activation of c-Met, down-regulation of Met-targeted miRNA, binding to other ligands, autocrine signaling or abnormally high HGF levels initiates and drives tumorigenesis and promotes tumor growth, invasion, metastasis, and angiogenesis in HCC. In the progression of liver cancer, c-Met is regulated by various factors such as miRNAs and SOCS1. Furthermore, c-Met cooperates with other signaling pathways such as MUCI or &#x003b2;-catenin in promoting tumorigenesis. Therefore, the treatment of liver cancer with c-Met as a target is a potential and promising therapy strategy. So far, six c-Met inhibitors have entered clinical trials and have been shown to inhibit tumor growth and invasion. Moreover, selective c-Met inhibitors are superior to non-selective c-Met inhibitors in the treatment of liver cancer due to their low toxicity. However, the failure of the tivantinib phase III trial suggests that we need to further study the causes of failure and the feasibility of c-Met inhibitors in treating HCC.</p><p>In addition, we should also consider the relationship between c-Met inhibitors and liver disease, although there is no clinical evidence that c-Met inhibitors worsen liver function. In chronic liver diseases, c-Met expression is increased to promote hepatocyte proliferation and inhibit inflammation. C-Met inhibitors suppress this positive regulation and may accelerate advanced liver disease. Meanwhile, liver diseases affect the drug pharmacokinetics, pharmacodynamics, reduce enzyme activity, impair hepatic clearance of drugs and even change the interplay between drugs. These effects may alter the dose of the drug needed to reach the desired blood concentration and induce novel toxicities. Thus, we should consider whether patients with Child-Pugh B or C disease can tolerate the dose established in clinical trials because in the past, most clinical trials were conducted in patients with Child-Pugh A disease.</p><p>Besides c-Met inhibitors, many new therapeutic strategies have been developed, such as the use of miRNAs to regulate HGF/c-Met signaling pathways to inhibit liver cancer progression, targeting endocytosis and more downstream molecules, Hic-5 as a therapeutic strategy to reduce side effects of c-Met inhibitors, as well as herbal treatments. c-Met is also involved in the resistance mechanism of sorafenib, which can be solved by the combination of c-Met inhibitor and sorafenib. For the self-resistance of c-Met inhibitors, the combination of c-Met inhibitors and other inhibitors can be used to solve this problem, such as FGFR and EGFT inhibitors, autophagy inhibitor and anti-PD1 treatment. Whether HGF/c-Met can be used as independent diagnostic and prognostic markers still requires further research, but HGF/c-Met in combination with other diagnostic and prognostic markers is valuable. In general, the mechanism of the HGF/c-Met pathway involvement in liver cancer requires more research, and c-Met inhibitors are a potential and promising therapeutic strategy in patients with HCC.</p></sec><sec id="S7"><title>Author Contributions</title><p>ZR and ZY proposed the study and the guarantors. HW, BR, and JL performed the research and wrote the first draft. All authors contributed to the interpretation of the study and to further drafts.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> The study was supported by the Henan Province Science and Technology Project (182102310112, ZY), the National S&#x00026;T Major Project of China (2018ZX10301201-008), National Natural Science Foundation of China (81600506), National Key Research and Development Program of China (2018YFC2000501), and China Postdoctoral Science Foundation (2017464 and 20182814). The funding sources had no role in the design of this study nor any role during its execution, analyses, data interpretation, or decision to submit results.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abella</surname><given-names>J. V.</given-names></name><name><surname>Peschard</surname><given-names>P.</given-names></name><name><surname>Naujokas</surname><given-names>M. A.</given-names></name><name><surname>Lin</surname><given-names>T.</given-names></name><name><surname>Saucier</surname><given-names>C.</given-names></name><name><surname>Urbe</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.</article-title>
<source><italic>Mol. Cell Biol.</italic></source>
<volume>25</volume>
<fpage>9632</fpage>&#x02013;<lpage>9645</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.25.21.9632-9645.2005</pub-id>
<?supplied-pmid 16227611?><pub-id pub-id-type="pmid">16227611</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abounader</surname><given-names>R.</given-names></name><name><surname>Laterra</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.</article-title>
<source><italic>Neuro Oncol.</italic></source>
<volume>7</volume>
<fpage>436</fpage>&#x02013;<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1215/s1152851705000050</pub-id>
<?supplied-pmid 16212809?><pub-id pub-id-type="pmid">16212809</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aebersold</surname><given-names>D. M.</given-names></name><name><surname>Landt</surname><given-names>O.</given-names></name><name><surname>Berthou</surname><given-names>S.</given-names></name><name><surname>Gruber</surname><given-names>G.</given-names></name><name><surname>Beer</surname><given-names>K. T.</given-names></name><name><surname>Greiner</surname><given-names>R. H.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx.</article-title>
<source><italic>Oncogene</italic></source>
<volume>22</volume>
<fpage>8519</fpage>&#x02013;<lpage>8523</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1206968</pub-id>
<?supplied-pmid 14627992?><pub-id pub-id-type="pmid">14627992</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoyama</surname><given-names>A.</given-names></name><name><surname>Katayama</surname><given-names>R.</given-names></name><name><surname>Oh-Hara</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>S.</given-names></name><name><surname>Okuno</surname><given-names>Y.</given-names></name><name><surname>Fujita</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.</article-title>
<source><italic>Mol. Cancer Ther.</italic></source>
<volume>13</volume>
<fpage>2978</fpage>&#x02013;<lpage>2990</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.Mct-14-0462</pub-id>
<?supplied-pmid 25313010?><pub-id pub-id-type="pmid">25313010</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basilico</surname><given-names>C.</given-names></name><name><surname>Hultberg</surname><given-names>A.</given-names></name><name><surname>Blanchetot</surname><given-names>C.</given-names></name><name><surname>de Jonge</surname><given-names>N.</given-names></name><name><surname>Festjens</surname><given-names>E.</given-names></name><name><surname>Hanssens</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Four individually druggable MET hotspots mediate HGF-driven tumor progression.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>124</volume>
<fpage>3172</fpage>&#x02013;<lpage>3186</lpage>. <pub-id pub-id-type="doi">10.1172/jci72316</pub-id>
<?supplied-pmid 24865428?><pub-id pub-id-type="pmid">24865428</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birchmeier</surname><given-names>C.</given-names></name><name><surname>Birchmeier</surname><given-names>W.</given-names></name><name><surname>Gherardi</surname><given-names>E.</given-names></name><name><surname>Vande Woude</surname><given-names>G. F.</given-names></name></person-group> (<year>2003</year>). <article-title>Met, metastasis, motility and more.</article-title>
<source><italic>Nat. Rev. Mol. Cell Biol.</italic></source>
<volume>4</volume>
<fpage>915</fpage>&#x02013;<lpage>925</lpage>. <pub-id pub-id-type="doi">10.1038/nrm1261</pub-id>
<?supplied-pmid 14685170?><pub-id pub-id-type="pmid">14685170</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bladt</surname><given-names>F.</given-names></name><name><surname>Friese-Hamim</surname><given-names>M.</given-names></name><name><surname>Ihling</surname><given-names>C.</given-names></name><name><surname>Wilm</surname><given-names>C.</given-names></name><name><surname>Blaukat</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>The c-Met inhibitor MSC2156119J effectively inhibits tumor growth in liver cancer models.</article-title>
<source><italic>Cancers</italic></source>
<volume>6</volume>
<fpage>1736</fpage>&#x02013;<lpage>1752</lpage>. <pub-id pub-id-type="doi">10.3390/cancers6031736</pub-id>
<?supplied-pmid 25256830?><pub-id pub-id-type="pmid">25256830</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blagotinsek</surname><given-names>K.</given-names></name><name><surname>Rozman</surname><given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Targeting signalling pathways in Hepatocellular Carcinoma.</article-title>
<source><italic>Curr. Pharm. Des.</italic></source>
<volume>23</volume>
<fpage>170</fpage>&#x02013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.2174/1381612822666161006160005</pub-id>
<?supplied-pmid 27719638?><pub-id pub-id-type="pmid">27719638</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boccaccio</surname><given-names>C.</given-names></name><name><surname>Comoglio</surname><given-names>P. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Invasive growth: a MET-driven genetic programme for cancer and stem cells.</article-title>
<source><italic>Nat. Rev. Cancer</italic></source>
<volume>6</volume>
<fpage>637</fpage>&#x02013;<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1912</pub-id>
<?supplied-pmid 16862193?><pub-id pub-id-type="pmid">16862193</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borowiak</surname><given-names>M.</given-names></name><name><surname>Garratt</surname><given-names>A. N.</given-names></name><name><surname>Wustefeld</surname><given-names>T.</given-names></name><name><surname>Strehle</surname><given-names>M.</given-names></name><name><surname>Trautwein</surname><given-names>C.</given-names></name><name><surname>Birchmeier</surname><given-names>C.</given-names></name></person-group> (<year>2004</year>). <article-title>Met provides essential signals for liver regeneration.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>101</volume>
<fpage>10608</fpage>&#x02013;<lpage>10613</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0403412101</pub-id>
<?supplied-pmid 15249655?><pub-id pub-id-type="pmid">15249655</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouattour</surname><given-names>M.</given-names></name><name><surname>Raymond</surname><given-names>E.</given-names></name><name><surname>Qin</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>A. L.</given-names></name><name><surname>Stammberger</surname><given-names>U.</given-names></name><name><surname>Locatelli</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.</article-title>
<source><italic>Hepatology</italic></source>
<volume>67</volume>
<fpage>1132</fpage>&#x02013;<lpage>1149</lpage>. <pub-id pub-id-type="doi">10.1002/hep.29496</pub-id>
<?supplied-pmid 28862760?><pub-id pub-id-type="pmid">28862760</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozkaya</surname><given-names>G.</given-names></name><name><surname>Korhan</surname><given-names>P.</given-names></name><name><surname>Cokakli</surname><given-names>M.</given-names></name><name><surname>Erdal</surname><given-names>E.</given-names></name><name><surname>Sagol</surname><given-names>O.</given-names></name><name><surname>Karademir</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.</article-title>
<source><italic>Mol. Cancer</italic></source>
<volume>11</volume>:<issue>64</issue>. <pub-id pub-id-type="doi">10.1186/1476-4598-11-64</pub-id>
<?supplied-pmid 22962849?><pub-id pub-id-type="pmid">22962849</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>C. A.</given-names></name><name><surname>Salto-Tellez</surname><given-names>M.</given-names></name><name><surname>Laurent-Puig</surname><given-names>P.</given-names></name><name><surname>Bardelli</surname><given-names>A.</given-names></name><name><surname>Rolfo</surname><given-names>C.</given-names></name><name><surname>Tabernero</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.</article-title>
<source><italic>Nat. Rev. Clin. Oncol.</italic></source>
<volume>14</volume>
<fpage>562</fpage>&#x02013;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1038/nrclinonc.2017.40</pub-id>
<?supplied-pmid 28374784?><pub-id pub-id-type="pmid">28374784</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J.</given-names></name><name><surname>Qin</surname><given-names>S.</given-names></name><name><surname>Merle</surname><given-names>P.</given-names></name><name><surname>Granito</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>Y. H.</given-names></name><name><surname>Bodoky</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.</article-title>
<source><italic>Lancet</italic></source>
<volume>389</volume>
<fpage>56</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(16)32453-32459</pub-id>
<?supplied-pmid 27932229?><pub-id pub-id-type="pmid">27932229</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buurman</surname><given-names>R.</given-names></name><name><surname>Gurlevik</surname><given-names>E.</given-names></name><name><surname>Schaffer</surname><given-names>V.</given-names></name><name><surname>Eilers</surname><given-names>M.</given-names></name><name><surname>Sandbothe</surname><given-names>M.</given-names></name><name><surname>Kreipe</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.</article-title>
<source><italic>Gastroenterology</italic></source>
<volume>143</volume>:<issue>e815</issue>. <pub-id pub-id-type="doi">10.1053/j.gastro.2012.05.033</pub-id>
<?supplied-pmid 22641068?><pub-id pub-id-type="pmid">22641068</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Miao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Jia</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5.</article-title>
<source><italic>Lab. Invest.</italic></source>
<volume>97</volume>
<fpage>530</fpage>&#x02013;<lpage>542</lpage>. <pub-id pub-id-type="doi">10.1038/labinvest.2017.12</pub-id>
<?supplied-pmid 28218742?><pub-id pub-id-type="pmid">28218742</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>miR-101 inhibiting cell proliferation, migration and invasion in hepatocellular carcinoma through downregulating girdin.</article-title>
<source><italic>Mol. Cells</italic></source>
<volume>39</volume>
<fpage>96</fpage>&#x02013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.14348/molcells.2016.2161</pub-id>
<?supplied-pmid 26743900?><pub-id pub-id-type="pmid">26743900</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>You</surname><given-names>J.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells.</article-title>
<source><italic>Acta Pharm. Sin. B</italic></source>
<volume>9</volume>
<fpage>484</fpage>&#x02013;<lpage>495</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2019.03.001</pub-id>
<?supplied-pmid 31193822?><pub-id pub-id-type="pmid">31193822</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H. A.</given-names></name><name><surname>Kuo</surname><given-names>T. C.</given-names></name><name><surname>Tseng</surname><given-names>C. F.</given-names></name><name><surname>Ma</surname><given-names>J. T.</given-names></name><name><surname>Yang</surname><given-names>S. T.</given-names></name><name><surname>Yen</surname><given-names>C. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.</article-title>
<source><italic>Hepatology</italic></source>
<volume>64</volume>
<fpage>1637</fpage>&#x02013;<lpage>1651</lpage>. <pub-id pub-id-type="doi">10.1002/hep.28773</pub-id>
<?supplied-pmid 27530187?><pub-id pub-id-type="pmid">27530187</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>). <article-title>Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met.</article-title>
<source><italic>J. Cell Physiol.</italic></source>
<volume>234</volume>
<fpage>14999</fpage>&#x02013;<lpage>15009</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.27567</pub-id>
<?supplied-pmid 30937906?><pub-id pub-id-type="pmid">30937906</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name></person-group> (<year>2019</year>). <article-title>Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma.</article-title>
<source><italic>FEBS Open Biol.</italic></source>
<volume>9</volume>
<fpage>335</fpage>&#x02013;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1002/2211-5463.12578</pub-id>
<?supplied-pmid 30761258?><pub-id pub-id-type="pmid">30761258</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>A. L.</given-names></name><name><surname>Kang</surname><given-names>Y. K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Tsao</surname><given-names>C. J.</given-names></name><name><surname>Qin</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.</article-title>
<source><italic>Lancet Oncol.</italic></source>
<volume>10</volume>
<fpage>25</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(08)70285-70287</pub-id>
<?supplied-pmid 19095497?><pub-id pub-id-type="pmid">19095497</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>C. S.</given-names></name><name><surname>Park</surname><given-names>M.</given-names></name><name><surname>Blair</surname><given-names>D. G.</given-names></name><name><surname>Tainsky</surname><given-names>M. A.</given-names></name><name><surname>Huebner</surname><given-names>K.</given-names></name><name><surname>Croce</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>1984</year>). <article-title>Molecular cloning of a new transforming gene from a chemically transformed human cell line.</article-title>
<source><italic>Nature</italic></source>
<volume>311</volume>
<fpage>29</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1038/311029a0</pub-id>
<?supplied-pmid 6590967?><pub-id pub-id-type="pmid">6590967</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corso</surname><given-names>S.</given-names></name><name><surname>Giordano</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective.</article-title>
<source><italic>Cancer Discov.</italic></source>
<volume>3</volume>
<fpage>978</fpage>&#x02013;<lpage>992</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.Cd-13-0040</pub-id>
<?supplied-pmid 23901039?><pub-id pub-id-type="pmid">23901039</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J. J.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Tran-Dube</surname><given-names>M.</given-names></name><name><surname>Nambu</surname><given-names>M.</given-names></name><name><surname>McTigue</surname><given-names>M.</given-names></name><name><surname>Grodsky</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>56</volume>
<fpage>6651</fpage>&#x02013;<lpage>6665</lpage>. <pub-id pub-id-type="doi">10.1021/jm400926x</pub-id>
<?supplied-pmid 23944843?><pub-id pub-id-type="pmid">23944843</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>D.</given-names></name><name><surname>Rong</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET.</article-title>
<source><italic>PLoS One</italic></source>
<volume>8</volume>:<issue>e61054</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0061054</pub-id>
<?supplied-pmid 23593387?><pub-id pub-id-type="pmid">23593387</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Renzo</surname><given-names>M. F.</given-names></name><name><surname>Olivero</surname><given-names>M.</given-names></name><name><surname>Martone</surname><given-names>T.</given-names></name><name><surname>Maffe</surname><given-names>A.</given-names></name><name><surname>Maggiora</surname><given-names>P.</given-names></name><name><surname>Stefani</surname><given-names>A. D.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.</article-title>
<source><italic>Oncogene</italic></source>
<volume>19</volume>
<fpage>1547</fpage>&#x02013;<lpage>1555</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1203455</pub-id>
<?supplied-pmid 10734314?><pub-id pub-id-type="pmid">10734314</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>You</surname><given-names>H.</given-names></name><name><surname>Dang</surname><given-names>H.</given-names></name><name><surname>LeBlanc</surname><given-names>F.</given-names></name><name><surname>Galicia</surname><given-names>V.</given-names></name><name><surname>Lu</surname><given-names>S. C.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion.</article-title>
<source><italic>Hepatology</italic></source>
<volume>52</volume>
<fpage>945</fpage>&#x02013;<lpage>953</lpage>. <pub-id pub-id-type="doi">10.1002/hep.23748</pub-id>
<?supplied-pmid 20564331?><pub-id pub-id-type="pmid">20564331</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>N.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Kuang</surname><given-names>Z.</given-names></name><name><surname>Xie</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma.</article-title>
<source><italic>Br. J. Cancer</italic></source>
<volume>121</volume>
<fpage>22</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1038/s41416-019-0482-x</pub-id>
<?supplied-pmid 31130723?><pub-id pub-id-type="pmid">31130723</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Z.</given-names></name><name><surname>Caenepeel</surname><given-names>S.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Rex</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Preclinical evaluation of AMG 337, a highly selective small molecule MET inhibitor, in hepatocellular carcinoma.</article-title>
<source><italic>Mol. Cancer Ther.</italic></source>
<volume>15</volume>
<fpage>1227</fpage>&#x02013;<lpage>1237</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.Mct-15-0745</pub-id>
<?supplied-pmid 27196749?><pub-id pub-id-type="pmid">27196749</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyson</surname><given-names>J.</given-names></name><name><surname>Jaques</surname><given-names>B.</given-names></name><name><surname>Chattopadyhay</surname><given-names>D.</given-names></name><name><surname>Lochan</surname><given-names>R.</given-names></name><name><surname>Graham</surname><given-names>J.</given-names></name><name><surname>Das</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.</article-title>
<source><italic>J. Hepatol.</italic></source>
<volume>60</volume>
<fpage>110</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2013.08.011</pub-id>
<?supplied-pmid 23978719?><pub-id pub-id-type="pmid">23978719</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Khoueiry</surname><given-names>A. B.</given-names></name><name><surname>Sangro</surname><given-names>B.</given-names></name><name><surname>Yau</surname><given-names>T.</given-names></name><name><surname>Crocenzi</surname><given-names>T. S.</given-names></name><name><surname>Kudo</surname><given-names>M.</given-names></name><name><surname>Hsu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.</article-title>
<source><italic>Lancet</italic></source>
<volume>389</volume>
<fpage>2492</fpage>&#x02013;<lpage>2502</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(17)31046-31042</pub-id>
<?supplied-pmid 28434648?><pub-id pub-id-type="pmid">28434648</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasolo</surname><given-names>A.</given-names></name><name><surname>Sessa</surname><given-names>C.</given-names></name><name><surname>Gianni</surname><given-names>L.</given-names></name><name><surname>Broggini</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist.</article-title>
<source><italic>Ann. Oncol.</italic></source>
<volume>24</volume>
<fpage>14</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mds520</pub-id>
<?supplied-pmid 23110808?><pub-id pub-id-type="pmid">23110808</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Colombet</surname><given-names>M.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Mathers</surname><given-names>C.</given-names></name><name><surname>Parkin</surname><given-names>D. M.</given-names></name><name><surname>Pineros</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.</article-title>
<source><italic>Int. J. Cancer</italic></source>
<volume>144</volume>
<fpage>1941</fpage>&#x02013;<lpage>1953</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.31937</pub-id>
<?supplied-pmid 30350310?><pub-id pub-id-type="pmid">30350310</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firtina Karagonlar</surname><given-names>Z.</given-names></name><name><surname>Koc</surname><given-names>D.</given-names></name><name><surname>Iscan</surname><given-names>E.</given-names></name><name><surname>Erdal</surname><given-names>E.</given-names></name><name><surname>Atabey</surname><given-names>N.</given-names></name></person-group> (<year>2016</year>). <article-title>Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.</article-title>
<source><italic>Cancer Sci.</italic></source>
<volume>107</volume>
<fpage>407</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1111/cas.12891</pub-id>
<?supplied-pmid 26790028?><pub-id pub-id-type="pmid">26790028</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>Fundamental concepts of the angiogenic process.</article-title>
<source><italic>Curr. Mol. Med.</italic></source>
<volume>3</volume>
<fpage>643</fpage>&#x02013;<lpage>651</lpage>. <pub-id pub-id-type="doi">10.2174/1566524033479465</pub-id>
<?supplied-pmid 14601638?><pub-id pub-id-type="pmid">14601638</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forner</surname><given-names>A.</given-names></name><name><surname>Reig</surname><given-names>M.</given-names></name><name><surname>Bruix</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Hepatocellular carcinoma.</article-title>
<source><italic>Lancet</italic></source>
<volume>391</volume>
<fpage>1301</fpage>&#x02013;<lpage>1314</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(18)30010-30012</pub-id>
<?supplied-pmid 29307467?><pub-id pub-id-type="pmid">29307467</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>R. C.</given-names></name><name><surname>Farh</surname><given-names>K. K.</given-names></name><name><surname>Burge</surname><given-names>C. B.</given-names></name><name><surname>Bartel</surname><given-names>D. P.</given-names></name></person-group> (<year>2009</year>). <article-title>Most mammalian mRNAs are conserved targets of microRNAs.</article-title>
<source><italic>Genome Res.</italic></source>
<volume>19</volume>
<fpage>92</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1101/gr.082701.108</pub-id>
<?supplied-pmid 18955434?><pub-id pub-id-type="pmid">18955434</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Deng</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.</article-title>
<source><italic>Oncol. Rep.</italic></source>
<volume>37</volume>
<fpage>1203</fpage>&#x02013;<lpage>1211</lpage>. <pub-id pub-id-type="doi">10.3892/or.2017.5347</pub-id>
<?supplied-pmid 28075467?><pub-id pub-id-type="pmid">28075467</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Inagaki</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>P.</given-names></name><name><surname>Qu</surname><given-names>X.</given-names></name><name><surname>Kokudo</surname><given-names>N.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.</article-title>
<source><italic>Pharmacol. Res.</italic></source>
<volume>65</volume>
<fpage>23</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2011.11.011</pub-id>
<?supplied-pmid 22138044?><pub-id pub-id-type="pmid">22138044</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Vilas</surname><given-names>J. A.</given-names></name><name><surname>Medina</surname><given-names>M. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.</article-title>
<source><italic>World J. Gastroenterol.</italic></source>
<volume>24</volume>
<fpage>3695</fpage>&#x02013;<lpage>3708</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v24.i33.3695</pub-id>
<?supplied-pmid 30197476?><pub-id pub-id-type="pmid">30197476</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghiso</surname><given-names>E.</given-names></name><name><surname>Giordano</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Targeting MET: why, where and how?</article-title>
<source><italic>Curr. Opin. Pharmacol.</italic></source>
<volume>13</volume>
<fpage>511</fpage>&#x02013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2013.05.018</pub-id>
<?supplied-pmid 23797036?><pub-id pub-id-type="pmid">23797036</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>S.</given-names></name><name><surname>Columbano</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Met as a therapeutic target in HCC: facts and hopes.</article-title>
<source><italic>J. Hepatol.</italic></source>
<volume>60</volume>
<fpage>442</fpage>&#x02013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2013.09.009</pub-id>
<?supplied-pmid 24045150?><pub-id pub-id-type="pmid">24045150</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>X. Y.</given-names></name><name><surname>Ma</surname><given-names>N.</given-names></name><name><surname>Xu</surname><given-names>H. X.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>X. H.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name></person-group> (<year>2018</year>). <article-title>Prognostic significance of c-Met, beta-catenin and FAK in patients with hepatocellular carcinoma following surgery.</article-title>
<source><italic>Oncol. Lett.</italic></source>
<volume>15</volume>
<fpage>3796</fpage>&#x02013;<lpage>3805</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2018.7733</pub-id>
<?supplied-pmid 29467897?><pub-id pub-id-type="pmid">29467897</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>M. N.</given-names></name><name><surname>de Mello</surname><given-names>W.</given-names></name><name><surname>Butler-Browne</surname><given-names>G. S.</given-names></name><name><surname>Silva-Barbosa</surname><given-names>S. D.</given-names></name><name><surname>Mouly</surname><given-names>V.</given-names></name><name><surname>Savino</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway.</article-title>
<source><italic>Skelet Muscle</italic></source>
<volume>7</volume>:<issue>20</issue>. <pub-id pub-id-type="doi">10.1186/s13395-017-0138-136</pub-id>
<?supplied-pmid 29017538?><pub-id pub-id-type="pmid">29017538</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>L.</given-names></name><name><surname>Muzumdar</surname><given-names>M. D.</given-names></name><name><surname>Zhu</surname><given-names>A. X.</given-names></name></person-group> (<year>2013</year>). <article-title>Targeting the HGF/c-MET pathway in hepatocellular carcinoma.</article-title>
<source><italic>Clin. Cancer Res.</italic></source>
<volume>19</volume>
<fpage>2310</fpage>&#x02013;<lpage>2318</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-12-2791</pub-id>
<?supplied-pmid 23388504?><pub-id pub-id-type="pmid">23388504</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graveel</surname><given-names>C. R.</given-names></name><name><surname>Tolbert</surname><given-names>D.</given-names></name><name><surname>Vande Woude</surname><given-names>G. F.</given-names></name></person-group> (<year>2013</year>). <article-title>MET: a critical player in tumorigenesis and therapeutic target.</article-title>
<source><italic>Cold Spring Harb. Perspect. Biol.</italic></source>
<volume>5</volume>:<issue>a009209</issue>. <pub-id pub-id-type="doi">10.1101/cshperspect.a009209</pub-id>
<?supplied-pmid 23818496?><pub-id pub-id-type="pmid">23818496</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>Y.</given-names></name><name><surname>Khan</surname><given-names>M. G. M.</given-names></name><name><surname>Bobbala</surname><given-names>D.</given-names></name><name><surname>Dubois</surname><given-names>C.</given-names></name><name><surname>Ramanathan</surname><given-names>S.</given-names></name><name><surname>Saucier</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.</article-title>
<source><italic>World J. Gastroenterol.</italic></source>
<volume>23</volume>
<fpage>6639</fpage>&#x02013;<lpage>6649</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v23.i36.6639</pub-id>
<?supplied-pmid 29085209?><pub-id pub-id-type="pmid">29085209</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>Y.</given-names></name><name><surname>Yeganeh</surname><given-names>M.</given-names></name><name><surname>Donates</surname><given-names>Y. C.</given-names></name><name><surname>Tobelaim</surname><given-names>W. S.</given-names></name><name><surname>Chababi</surname><given-names>W.</given-names></name><name><surname>Mayhue</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.</article-title>
<source><italic>Oncogene</italic></source>
<volume>34</volume>
<fpage>5718</fpage>&#x02013;<lpage>5728</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2015.20</pub-id>
<?supplied-pmid 25728680?><pub-id pub-id-type="pmid">25728680</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>Y.</given-names></name><name><surname>Yeganeh</surname><given-names>M.</given-names></name><name><surname>Ramanathan</surname><given-names>S.</given-names></name><name><surname>Leblanc</surname><given-names>C.</given-names></name><name><surname>Pomerleau</surname><given-names>V.</given-names></name><name><surname>Ferbeyre</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes.</article-title>
<source><italic>J. Hepatol.</italic></source>
<volume>55</volume>
<fpage>1300</fpage>&#x02013;<lpage>1308</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2011.03.027</pub-id>
<?supplied-pmid 21703184?><pub-id pub-id-type="pmid">21703184</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Zhai</surname><given-names>B.</given-names></name><name><surname>Tan</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.</article-title>
<source><italic>Mol. Oncol.</italic></source>
<volume>11</volume>
<fpage>320</fpage>&#x02013;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1002/1878-0261.12039</pub-id>
<?supplied-pmid 28164434?><pub-id pub-id-type="pmid">28164434</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Peng</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>X. Z.</given-names></name><name><surname>Shi</surname><given-names>D. C.</given-names></name><name><surname>Wang</surname><given-names>J. C.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma.</article-title>
<source><italic>Oncoimmunology</italic></source>
<volume>5</volume>:<issue>e1219828</issue>. <pub-id pub-id-type="doi">10.1080/2162402x.2016.1219828</pub-id>
<?supplied-pmid 27853643?><pub-id pub-id-type="pmid">27853643</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>J. C.</given-names></name><name><surname>Park</surname><given-names>J. K.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Nagorney</surname><given-names>D. M.</given-names></name><name><surname>Roberts</surname><given-names>L. R.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.</article-title>
<source><italic>Biochem. Biophys. Res. Commun.</italic></source>
<volume>403</volume>
<fpage>120</fpage>&#x02013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2010.10.130</pub-id>
<?supplied-pmid 21055388?><pub-id pub-id-type="pmid">21055388</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C. T.</given-names></name><name><surname>Cheng</surname><given-names>C. C.</given-names></name><name><surname>Wu</surname><given-names>J. R.</given-names></name><name><surname>Pan</surname><given-names>S. M.</given-names></name><name><surname>Wu</surname><given-names>W. S.</given-names></name></person-group> (<year>2015</year>). <article-title>PKCepsilon-mediated c-Met endosomal processing directs fluctuant c-Met-JNK-paxillin signaling for tumor progression of HepG2.</article-title>
<source><italic>Cell Signal.</italic></source>
<volume>27</volume>
<fpage>1544</fpage>&#x02013;<lpage>1555</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2015.02.031</pub-id>
<?supplied-pmid 25778903?><pub-id pub-id-type="pmid">25778903</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C. T.</given-names></name><name><surname>Wu</surname><given-names>J. R.</given-names></name><name><surname>Cheng</surname><given-names>C. C.</given-names></name><name><surname>Wu</surname><given-names>W. S.</given-names></name></person-group> (<year>2017</year>). <article-title>The therapeutic targeting of HGF/c-Met signaling in hepatocellular carcinoma: alternative approaches.</article-title>
<source><italic>Cancers</italic></source>
<volume>9</volume>:<issue>58</issue>. <pub-id pub-id-type="doi">10.3390/cancers9060058</pub-id>
<?supplied-pmid 28587113?><pub-id pub-id-type="pmid">28587113</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Gan</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name></person-group> (<year>2019</year>). <article-title>The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.</article-title>
<source><italic>Autophagy</italic></source>
<volume>15</volume>
<fpage>1258</fpage>&#x02013;<lpage>1279</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2019.1580105</pub-id>
<?supplied-pmid 30786811?><pub-id pub-id-type="pmid">30786811</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janevska</surname><given-names>D.</given-names></name><name><surname>Chaloska-Ivanova</surname><given-names>V.</given-names></name><name><surname>Janevski</surname><given-names>V.</given-names></name></person-group> (<year>2015</year>). <article-title>Hepatocellular carcinoma: risk factors, diagnosis and treatment.</article-title>
<source><italic>Open Access. Maced. J. Med. Sci.</italic></source>
<volume>3</volume>
<fpage>732</fpage>&#x02013;<lpage>736</lpage>. <pub-id pub-id-type="doi">10.3889/oamjms.2015.111</pub-id>
<?supplied-pmid 27275318?><pub-id pub-id-type="pmid">27275318</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Yin</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>miR-93 enhances hepatocellular carcinoma invasion and metastasis by EMT via targeting PDCD4.</article-title>
<source><italic>Biotechnol. Lett.</italic></source>
<volume>39</volume>
<fpage>1621</fpage>&#x02013;<lpage>1629</lpage>. <pub-id pub-id-type="doi">10.1007/s10529-017-2403-2405</pub-id>
<?supplied-pmid 28748353?><pub-id pub-id-type="pmid">28748353</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>C. C.</given-names></name><name><surname>Wang</surname><given-names>T. T.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Fu</surname><given-names>B. S.</given-names></name><name><surname>Hua</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>G. Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion.</article-title>
<source><italic>PLoS One</italic></source>
<volume>8</volume>:<issue>e63243</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0063243</pub-id>
<?supplied-pmid 23667593?><pub-id pub-id-type="pmid">23667593</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>J. C.</given-names></name><name><surname>Choi</surname><given-names>E. K.</given-names></name><name><surname>Shin</surname><given-names>J. S.</given-names></name><name><surname>Moon</surname><given-names>J. H.</given-names></name><name><surname>Hong</surname><given-names>S. W.</given-names></name><name><surname>Lee</surname><given-names>H. R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Targeting FGFR pathway in human hepatocellular carcinoma: expressing pFGFR and pMET for antitumor activity.</article-title>
<source><italic>Mol. Cancer Ther.</italic></source>
<volume>14</volume>
<fpage>2613</fpage>&#x02013;<lpage>2622</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.Mct-14-0780</pub-id>
<?supplied-pmid 26351320?><pub-id pub-id-type="pmid">26351320</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junbo</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zaide</surname><given-names>W.</given-names></name><name><surname>Yunde</surname><given-names>H.</given-names></name></person-group> (<year>1999</year>). <article-title>Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis.</article-title>
<source><italic>In Vivo</italic></source>
<volume>13</volume>
<fpage>177</fpage>&#x02013;<lpage>180</lpage>. <?supplied-pmid 10363175?><pub-id pub-id-type="pmid">10363175</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y. K.</given-names></name><name><surname>Yau</surname><given-names>T.</given-names></name><name><surname>Park</surname><given-names>J. W.</given-names></name><name><surname>Lim</surname><given-names>H. Y.</given-names></name><name><surname>Lee</surname><given-names>T. Y.</given-names></name><name><surname>Obi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.</article-title>
<source><italic>Ann. Oncol.</italic></source>
<volume>26</volume>
<fpage>2457</fpage>&#x02013;<lpage>2463</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdv388</pub-id>
<?supplied-pmid 26386123?><pub-id pub-id-type="pmid">26386123</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaposi-Novak</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>J. S.</given-names></name><name><surname>Gomez-Quiroz</surname><given-names>L.</given-names></name><name><surname>Coulouarn</surname><given-names>C.</given-names></name><name><surname>Factor</surname><given-names>V. M.</given-names></name><name><surname>Thorgeirsson</surname><given-names>S. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>116</volume>
<fpage>1582</fpage>&#x02013;<lpage>1595</lpage>. <pub-id pub-id-type="doi">10.1172/jci27236</pub-id>
<?supplied-pmid 16710476?><pub-id pub-id-type="pmid">16710476</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karabulut</surname><given-names>S.</given-names></name><name><surname>Tas</surname><given-names>F.</given-names></name><name><surname>Akyuz</surname><given-names>F.</given-names></name><name><surname>Ormeci</surname><given-names>A. C.</given-names></name><name><surname>Serilmez</surname><given-names>M.</given-names></name><name><surname>Soydinc</surname><given-names>H. O.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma.</article-title>
<source><italic>Tumour Biol.</italic></source>
<volume>35</volume>
<fpage>2327</fpage>&#x02013;<lpage>2333</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-013-1308-1308</pub-id>
<?supplied-pmid 24142532?><pub-id pub-id-type="pmid">24142532</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagonlar</surname><given-names>Z. F.</given-names></name><name><surname>Korhan</surname><given-names>P.</given-names></name><name><surname>Atabey</surname><given-names>N.</given-names></name></person-group> (<year>2015</year>). <article-title>Targeting c-met in cancer by MicroRNAs: potential therapeutic applications in hepatocellular carcinoma.</article-title>
<source><italic>Drug Dev. Res.</italic></source>
<volume>76</volume>
<fpage>357</fpage>&#x02013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1002/ddr.21274</pub-id>
<?supplied-pmid 26363180?><pub-id pub-id-type="pmid">26363180</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>A. W.</given-names></name><name><surname>Shi</surname><given-names>G. M.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>F. Z.</given-names></name><name><surname>Ding</surname><given-names>Z. B.</given-names></name><name><surname>Hu</surname><given-names>M. Y.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.</article-title>
<source><italic>Hepatology</italic></source>
<volume>49</volume>
<fpage>491</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1002/hep.22639</pub-id>
<?supplied-pmid 19065669?><pub-id pub-id-type="pmid">19065669</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kentsis</surname><given-names>A.</given-names></name><name><surname>Reed</surname><given-names>C.</given-names></name><name><surname>Rice</surname><given-names>K. L.</given-names></name><name><surname>Sanda</surname><given-names>T.</given-names></name><name><surname>Rodig</surname><given-names>S. J.</given-names></name><name><surname>Tholouli</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>18</volume>
<fpage>1118</fpage>&#x02013;<lpage>1122</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2819</pub-id>
<?supplied-pmid 22683780?><pub-id pub-id-type="pmid">22683780</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kermorgant</surname><given-names>S.</given-names></name><name><surname>Zicha</surname><given-names>D.</given-names></name><name><surname>Parker</surname><given-names>P. J.</given-names></name></person-group> (<year>2004</year>). <article-title>PKC controls HGF-dependent c-Met traffic, signalling and cell migration.</article-title>
<source><italic>EMBO J.</italic></source>
<volume>23</volume>
<fpage>3721</fpage>&#x02013;<lpage>3734</lpage>. <pub-id pub-id-type="doi">10.1038/sj.emboj.7600396</pub-id>
<?supplied-pmid 15385963?><pub-id pub-id-type="pmid">15385963</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>S.</given-names></name><name><surname>Ojima</surname><given-names>H.</given-names></name><name><surname>Tsuda</surname><given-names>H.</given-names></name><name><surname>Hashimoto</surname><given-names>J.</given-names></name><name><surname>Morizane</surname><given-names>C.</given-names></name><name><surname>Ikeda</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma.</article-title>
<source><italic>Int. J. Clin. Oncol.</italic></source>
<volume>18</volume>
<fpage>207</fpage>&#x02013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1007/s10147-011-0361-369</pub-id>
<?supplied-pmid 22218908?><pub-id pub-id-type="pmid">22218908</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korhan</surname><given-names>P.</given-names></name><name><surname>Erdal</surname><given-names>E.</given-names></name><name><surname>Atabey</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.</article-title>
<source><italic>Biochem. Biophys. Res. Commun.</italic></source>
<volume>450</volume>
<fpage>1304</fpage>&#x02013;<lpage>1312</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.06.142</pub-id>
<?supplied-pmid 25058462?><pub-id pub-id-type="pmid">25058462</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M.</given-names></name><name><surname>Finn</surname><given-names>R. S.</given-names></name><name><surname>Qin</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>K. H.</given-names></name><name><surname>Ikeda</surname><given-names>K.</given-names></name><name><surname>Piscaglia</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.</article-title>
<source><italic>Lancet</italic></source>
<volume>391</volume>
<fpage>1163</fpage>&#x02013;<lpage>1173</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(18)30207-30201</pub-id>
<?supplied-pmid 29433850?><pub-id pub-id-type="pmid">29433850</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M.</given-names></name><name><surname>Han</surname><given-names>G.</given-names></name><name><surname>Finn</surname><given-names>R. S.</given-names></name><name><surname>Poon</surname><given-names>R. T.</given-names></name><name><surname>Blanc</surname><given-names>J. F.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial.</article-title>
<source><italic>Hepatology</italic></source>
<volume>60</volume>
<fpage>1697</fpage>&#x02013;<lpage>1707</lpage>. <pub-id pub-id-type="doi">10.1002/hep.27290</pub-id>
<?supplied-pmid 24996197?><pub-id pub-id-type="pmid">24996197</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladeiro</surname><given-names>Y.</given-names></name><name><surname>Couchy</surname><given-names>G.</given-names></name><name><surname>Balabaud</surname><given-names>C.</given-names></name><name><surname>Bioulac-Sage</surname><given-names>P.</given-names></name><name><surname>Pelletier</surname><given-names>L.</given-names></name><name><surname>Rebouissou</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.</article-title>
<source><italic>Hepatology</italic></source>
<volume>47</volume>
<fpage>1955</fpage>&#x02013;<lpage>1963</lpage>. <pub-id pub-id-type="doi">10.1002/hep.22256</pub-id>
<?supplied-pmid 18433021?><pub-id pub-id-type="pmid">18433021</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. H.</given-names></name><name><surname>Han</surname><given-names>S. U.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Jennings</surname><given-names>B.</given-names></name><name><surname>Gerrard</surname><given-names>B.</given-names></name><name><surname>Dean</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>A novel germ line juxtamembrane Met mutation in human gastric cancer.</article-title>
<source><italic>Oncogene</italic></source>
<volume>19</volume>
<fpage>4947</fpage>&#x02013;<lpage>4953</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1203874</pub-id>
<?supplied-pmid 11042681?><pub-id pub-id-type="pmid">11042681</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K. H.</given-names></name><name><surname>Hyun</surname><given-names>M. S.</given-names></name><name><surname>Kim</surname><given-names>J. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.</article-title>
<source><italic>Clin. Exp. Metastasis</italic></source>
<volume>20</volume>
<fpage>499</fpage>&#x02013;<lpage>505</lpage>. <?supplied-pmid 14598883?><pub-id pub-id-type="pmid">14598883</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>C. W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ding</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1.</article-title>
<source><italic>Gastroenterology</italic></source>
<volume>156</volume>:<issue>1849-1861.e13</issue>. <pub-id pub-id-type="doi">10.1053/j.gastro.2019.01.252</pub-id>
<?supplied-pmid 30711629?><pub-id pub-id-type="pmid">30711629</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>). <article-title>The Role of upregulated DDX11 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma.</article-title>
<source><italic>J. Cancer</italic></source>
<volume>10</volume>
<fpage>4208</fpage>&#x02013;<lpage>4216</lpage>. <pub-id pub-id-type="doi">10.7150/jca.33457</pub-id>
<?supplied-pmid 31413739?><pub-id pub-id-type="pmid">31413739</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Deng</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway.</article-title>
<source><italic>Oncotarget</italic></source>
<volume>9</volume>
<fpage>152</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.22077</pub-id>
<?supplied-pmid 29416603?><pub-id pub-id-type="pmid">29416603</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>You</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Madecassoside suppresses proliferation and invasiveness of HGF-induced human hepatocellular carcinoma cells via PKC-cMET-ERK1/2-COX-2-PGE2 pathway.</article-title>
<source><italic>Int. Immunopharmacol.</italic></source>
<volume>33</volume>
<fpage>24</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2016.01.027</pub-id>
<?supplied-pmid 26851630?><pub-id pub-id-type="pmid">26851630</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Zong</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>X. F.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>beta-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic beta-catenin and MET.</article-title>
<source><italic>Hepatology</italic></source>
<volume>67</volume>
<fpage>1807</fpage>&#x02013;<lpage>1822</lpage>. <pub-id pub-id-type="doi">10.1002/hep.29661</pub-id>
<?supplied-pmid 29152756?><pub-id pub-id-type="pmid">29152756</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liotta</surname><given-names>L. A.</given-names></name><name><surname>Kohn</surname><given-names>E. C.</given-names></name></person-group> (<year>2001</year>). <article-title>The microenvironment of the tumour-host interface.</article-title>
<source><italic>Nature</italic></source>
<volume>411</volume>
<fpage>375</fpage>&#x02013;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1038/35077241</pub-id>
<?supplied-pmid 11357145?><pub-id pub-id-type="pmid">11357145</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J. J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>W. S.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Zong</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic beta-Catenin, PIK3CA and MET.</article-title>
<source><italic>J. Hepatol.</italic></source>
<volume>69</volume>
<fpage>79</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2018.02.014</pub-id>
<?supplied-pmid 29505847?><pub-id pub-id-type="pmid">29505847</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W. T.</given-names></name><name><surname>Jing</surname><given-names>Y. Y.</given-names></name><name><surname>Yu</surname><given-names>G. F.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Han</surname><given-names>Z. P.</given-names></name><name><surname>Yu</surname><given-names>D. D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53.</article-title>
<source><italic>Cell Cycle</italic></source>
<volume>15</volume>
<fpage>886</fpage>&#x02013;<lpage>894</lpage>. <pub-id pub-id-type="doi">10.1080/15384101.2016.1152428</pub-id>
<?supplied-pmid 27077227?><pub-id pub-id-type="pmid">27077227</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Ou</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.</article-title>
<source><italic>Invest. New Drugs</italic></source>
<pub-id pub-id-type="doi">10.1007/s10637-019-00766-768</pub-id>
<comment>[Epub ahead of print]</comment>
<?supplied-pmid 30929159?><pub-id pub-id-type="pmid">30929159</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>J. M.</given-names></name><name><surname>Ricci</surname><given-names>S.</given-names></name><name><surname>Mazzaferro</surname><given-names>V.</given-names></name><name><surname>Hilgard</surname><given-names>P.</given-names></name><name><surname>Gane</surname><given-names>E.</given-names></name><name><surname>Blanc</surname><given-names>J. F.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Sorafenib in advanced hepatocellular carcinoma.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>359</volume>
<fpage>378</fpage>&#x02013;<lpage>390</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0708857</pub-id>
<?supplied-pmid 18650514?><pub-id pub-id-type="pmid">18650514</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>J. M.</given-names></name><name><surname>Villanueva</surname><given-names>A.</given-names></name><name><surname>Lachenmayer</surname><given-names>A.</given-names></name><name><surname>Finn</surname><given-names>R. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Advances in targeted therapies for hepatocellular carcinoma in the genomic era.</article-title>
<source><italic>Nat. Rev. Clin. Oncol.</italic></source>
<volume>12</volume>:<issue>436</issue>. <pub-id pub-id-type="doi">10.1038/nrclinonc.2015.121</pub-id>
<?supplied-pmid 26099984?><pub-id pub-id-type="pmid">26099984</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>S. G.</given-names></name><name><surname>Zhu</surname><given-names>L. F.</given-names></name><name><surname>Zhang</surname><given-names>F. X.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.</article-title>
<source><italic>J. Exp. Clin. Cancer Res.</italic></source>
<volume>38</volume>:<issue>130</issue>. <pub-id pub-id-type="doi">10.1186/s13046-019-1104-1104</pub-id>
<?supplied-pmid 30885237?><pub-id pub-id-type="pmid">30885237</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells.</article-title>
<source><italic>Biomed. Pharmacother.</italic></source>
<volume>101</volume>
<fpage>648</fpage>&#x02013;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.118</pub-id>
<?supplied-pmid 29518611?><pub-id pub-id-type="pmid">29518611</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marisi</surname><given-names>G.</given-names></name><name><surname>Petracci</surname><given-names>E.</given-names></name><name><surname>Raimondi</surname><given-names>F.</given-names></name><name><surname>Faloppi</surname><given-names>L.</given-names></name><name><surname>Foschi</surname><given-names>F. G.</given-names></name><name><surname>Lauletta</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib.</article-title>
<source><italic>Cancers</italic></source>
<volume>11</volume>:<issue>E1023</issue>. <pub-id pub-id-type="doi">10.3390/cancers11071023</pub-id>
<?supplied-pmid 31330833?><pub-id pub-id-type="pmid">31330833</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maroun</surname><given-names>C. R.</given-names></name><name><surname>Rowlands</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.</article-title>
<source><italic>Pharmacol. Ther.</italic></source>
<volume>142</volume>
<fpage>316</fpage>&#x02013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.12.014</pub-id>
<?supplied-pmid 24384534?><pub-id pub-id-type="pmid">24384534</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marquardt</surname><given-names>J. U.</given-names></name><name><surname>Thorgeirsson</surname><given-names>S. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Linking MLL and the HGF-MET signaling pathway in liver cancer.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>123</volume>
<fpage>2780</fpage>&#x02013;<lpage>2783</lpage>. <pub-id pub-id-type="doi">10.1172/jci70235</pub-id>
<?supplied-pmid 23934122?><pub-id pub-id-type="pmid">23934122</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marx-Stoelting</surname><given-names>P.</given-names></name><name><surname>Borowiak</surname><given-names>M.</given-names></name><name><surname>Knorpp</surname><given-names>T.</given-names></name><name><surname>Birchmeier</surname><given-names>C.</given-names></name><name><surname>Buchmann</surname><given-names>A.</given-names></name><name><surname>Schwarz</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met.</article-title>
<source><italic>Int. J. Cancer</italic></source>
<volume>124</volume>
<fpage>1767</fpage>&#x02013;<lpage>1772</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.24167</pub-id>
<?supplied-pmid 19123478?><pub-id pub-id-type="pmid">19123478</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mas</surname><given-names>V. R.</given-names></name><name><surname>Maluf</surname><given-names>D. G.</given-names></name><name><surname>Archer</surname><given-names>K. J.</given-names></name><name><surname>Yanek</surname><given-names>K. C.</given-names></name><name><surname>Fisher</surname><given-names>R. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation.</article-title>
<source><italic>Transplantation</italic></source>
<volume>84</volume>
<fpage>1262</fpage>&#x02013;<lpage>1271</lpage>. <pub-id pub-id-type="doi">10.1097/01.tp.0000287596.91520.1a</pub-id>
<?supplied-pmid 18049111?><pub-id pub-id-type="pmid">18049111</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name><name><surname>Sakai</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.</article-title>
<source><italic>Proteomics</italic></source>
<volume>8</volume>
<fpage>3360</fpage>&#x02013;<lpage>3370</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.200800156</pub-id>
<?supplied-pmid 18646008?><pub-id pub-id-type="pmid">18646008</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>H. T.</given-names></name><name><surname>Boucrot</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular mechanism and physiological functions of clathrin-mediated endocytosis.</article-title>
<source><italic>Nat. Rev. Mol. Cell Biol.</italic></source>
<volume>12</volume>
<fpage>517</fpage>&#x02013;<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3151</pub-id>
<?supplied-pmid 21779028?><pub-id pub-id-type="pmid">21779028</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migliore</surname><given-names>C.</given-names></name><name><surname>Giordano</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Molecular cancer therapy: can our expectation be MET?</article-title>
<source><italic>Eur. J. Cancer</italic></source>
<volume>44</volume>
<fpage>641</fpage>&#x02013;<lpage>651</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2008.01.022</pub-id>
<?supplied-pmid 18295476?><pub-id pub-id-type="pmid">18295476</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munshi</surname><given-names>N.</given-names></name><name><surname>Jeay</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>C. R.</given-names></name><name><surname>France</surname><given-names>D. S.</given-names></name><name><surname>Ashwell</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.</article-title>
<source><italic>Mol. Cancer Ther.</italic></source>
<volume>9</volume>
<fpage>1544</fpage>&#x02013;<lpage>1553</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.Mct-09-1173</pub-id>
<?supplied-pmid 20484018?><pub-id pub-id-type="pmid">20484018</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>Y.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Saigo</surname><given-names>K.</given-names></name><name><surname>Urashima</surname><given-names>T.</given-names></name><name><surname>Toyoda</surname><given-names>H.</given-names></name><name><surname>Okanoue</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.</article-title>
<source><italic>Oncogene</italic></source>
<volume>25</volume>
<fpage>2537</fpage>&#x02013;<lpage>2545</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1209283</pub-id>
<?supplied-pmid 16331254?><pub-id pub-id-type="pmid">16331254</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>O.</given-names></name><name><surname>Beraza</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.</article-title>
<source><italic>Gut</italic></source>
<volume>68</volume>
<fpage>1728</fpage>&#x02013;<lpage>1730</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2019-318999</pub-id>
<?supplied-pmid 31270163?><pub-id pub-id-type="pmid">31270163</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T.</given-names></name><name><surname>Nawa</surname><given-names>K.</given-names></name><name><surname>Ichihara</surname><given-names>A.</given-names></name></person-group> (<year>1984</year>). <article-title>Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats.</article-title>
<source><italic>Biochem. Biophys. Res. Commun.</italic></source>
<volume>122</volume>
<fpage>1450</fpage>&#x02013;<lpage>1459</lpage>. <pub-id pub-id-type="doi">10.1016/0006-291x(84)91253-91251</pub-id>
<?supplied-pmid 6477569?><pub-id pub-id-type="pmid">6477569</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>K.</given-names></name><name><surname>Hoshino</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ono</surname><given-names>S.</given-names></name><name><surname>Iida</surname><given-names>Y.</given-names></name><name><surname>Hata</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.</article-title>
<source><italic>Oncotarget</italic></source>
<volume>6</volume>
<fpage>3211</fpage>&#x02013;<lpage>3224</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.3085</pub-id>
<?supplied-pmid 25633810?><pub-id pub-id-type="pmid">25633810</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuma</surname><given-names>H. S.</given-names></name><name><surname>Kondo</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Trends in the development of MET inhibitors for hepatocellular carcinoma.</article-title>
<source><italic>Future Oncol.</italic></source>
<volume>12</volume>
<fpage>1275</fpage>&#x02013;<lpage>1286</lpage>. <pub-id pub-id-type="doi">10.2217/fon.16.3</pub-id>
<?supplied-pmid 26984595?><pub-id pub-id-type="pmid">26984595</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>W. S.</given-names></name><name><surname>Dong</surname><given-names>S. M.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name><name><surname>Na</surname><given-names>E. Y.</given-names></name><name><surname>Shin</surname><given-names>M. S.</given-names></name><name><surname>Pi</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.</article-title>
<source><italic>Cancer Res.</italic></source>
<volume>59</volume>
<fpage>307</fpage>&#x02013;<lpage>310</lpage>. <?supplied-pmid 9927037?><pub-id pub-id-type="pmid">9927037</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascale</surname><given-names>R. M.</given-names></name><name><surname>Feo</surname><given-names>F.</given-names></name><name><surname>Calvisi</surname><given-names>D. F.</given-names></name></person-group> (<year>2016</year>). <article-title>An infernal cross-talk between oncogenic beta-catenin and c-Met in hepatocellular carcinoma: evidence from mouse modeling.</article-title>
<source><italic>Hepatology</italic></source>
<volume>64</volume>
<fpage>1421</fpage>&#x02013;<lpage>1423</lpage>. <pub-id pub-id-type="doi">10.1002/hep.28790</pub-id>
<?supplied-pmid 27596836?><pub-id pub-id-type="pmid">27596836</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennacchietti</surname><given-names>S.</given-names></name><name><surname>Michieli</surname><given-names>P.</given-names></name><name><surname>Galluzzo</surname><given-names>M.</given-names></name><name><surname>Mazzone</surname><given-names>M.</given-names></name><name><surname>Giordano</surname><given-names>S.</given-names></name><name><surname>Comoglio</surname><given-names>P. M.</given-names></name></person-group> (<year>2003</year>). <article-title>Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.</article-title>
<source><italic>Cancer Cell</italic></source>
<volume>3</volume>
<fpage>347</fpage>&#x02013;<lpage>361</lpage>. <?supplied-pmid 12726861?><pub-id pub-id-type="pmid">12726861</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peschard</surname><given-names>P.</given-names></name><name><surname>Park</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>From Tpr-Met to Met, tumorigenesis and tubes.</article-title>
<source><italic>Oncogene</italic></source>
<volume>26</volume>
<fpage>1276</fpage>&#x02013;<lpage>1285</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1210201</pub-id>
<?supplied-pmid 17322912?><pub-id pub-id-type="pmid">17322912</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Cai</surname><given-names>P.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group> (<year>2018</year>). <article-title>Cinobufacini inhibits epithelial-mesenchymal transition of human hepatocellular carcinoma cells through c-Met/ERK signaling pathway.</article-title>
<source><italic>Biosci. Trends</italic></source>
<volume>12</volume>
<fpage>291</fpage>&#x02013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2018.01082</pub-id>
<?supplied-pmid 29794405?><pub-id pub-id-type="pmid">29794405</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Karagoz</surname><given-names>E.</given-names></name><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Shang</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Axis inhibition protein 1 (Axin1) deletion-induced hepatocarcinogenesis requires intact beta-catenin but not notch cascade in mice.</article-title>
<source><italic>Hepatology</italic></source>
<volume>70</volume>
<fpage>2003</fpage>&#x02013;<lpage>2017</lpage>. <pub-id pub-id-type="doi">10.1002/hep.30556</pub-id>
<?supplied-pmid 30737831?><pub-id pub-id-type="pmid">30737831</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remsing Rix</surname><given-names>L. L.</given-names></name><name><surname>Kuenzi</surname><given-names>B. M.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Remily-Wood</surname><given-names>E.</given-names></name><name><surname>Kinose</surname><given-names>F.</given-names></name><name><surname>Wright</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.</article-title>
<source><italic>ACS Chem. Biol.</italic></source>
<volume>9</volume>
<fpage>353</fpage>&#x02013;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1021/cb400660a</pub-id>
<?supplied-pmid 24215125?><pub-id pub-id-type="pmid">24215125</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Hong</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nanoparticle conjugation of ginsenoside Rg3 inhibits hepatocellular carcinoma development and metastasis.</article-title>
<source><italic>Small</italic></source>
<volume>16</volume>:<issue>e1905233</issue>. <pub-id pub-id-type="doi">10.1002/smll.201905233</pub-id>
<?supplied-pmid 31814271?><pub-id pub-id-type="pmid">31814271</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimassa</surname><given-names>L.</given-names></name><name><surname>Assenat</surname><given-names>E.</given-names></name><name><surname>Peck-Radosavljevic</surname><given-names>M.</given-names></name><name><surname>Pracht</surname><given-names>M.</given-names></name><name><surname>Zagonel</surname><given-names>V.</given-names></name><name><surname>Mathurin</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.</article-title>
<source><italic>Lancet Oncol.</italic></source>
<volume>19</volume>
<fpage>682</fpage>&#x02013;<lpage>693</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(18)30146-30143</pub-id>
<?supplied-pmid 29625879?><pub-id pub-id-type="pmid">29625879</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>G. A.</given-names></name><name><surname>Park</surname><given-names>M.</given-names></name><name><surname>Schlessinger</surname><given-names>J.</given-names></name></person-group> (<year>1997</year>). <article-title>Activation of the JNK pathway is essential for transformation by the Met oncogene.</article-title>
<source><italic>EMBO J.</italic></source>
<volume>16</volume>
<fpage>2634</fpage>&#x02013;<lpage>2645</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/16.10.2634</pub-id>
<?supplied-pmid 9184210?><pub-id pub-id-type="pmid">9184210</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>A.</given-names></name><name><surname>Rimassa</surname><given-names>L.</given-names></name><name><surname>Borbath</surname><given-names>I.</given-names></name><name><surname>Daniele</surname><given-names>B.</given-names></name><name><surname>Salvagni</surname><given-names>S.</given-names></name><name><surname>Van Laethem</surname><given-names>J. L.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.</article-title>
<source><italic>Lancet Oncol.</italic></source>
<volume>14</volume>
<fpage>55</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(12)70490-70494</pub-id>
<?supplied-pmid 23182627?><pub-id pub-id-type="pmid">23182627</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saucier</surname><given-names>C.</given-names></name><name><surname>Khoury</surname><given-names>H.</given-names></name><name><surname>Lai</surname><given-names>K. M.</given-names></name><name><surname>Peschard</surname><given-names>P.</given-names></name><name><surname>Dankort</surname><given-names>D.</given-names></name><name><surname>Naujokas</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>101</volume>
<fpage>2345</fpage>&#x02013;<lpage>2350</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0308065101</pub-id>
<?supplied-pmid 14983012?><pub-id pub-id-type="pmid">14983012</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scagliotti</surname><given-names>G. V.</given-names></name><name><surname>Novello</surname><given-names>S.</given-names></name><name><surname>von Pawel</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>The emerging role of MET/HGF inhibitors in oncology.</article-title>
<source><italic>Cancer Treat. Rev.</italic></source>
<volume>39</volume>
<fpage>793</fpage>&#x02013;<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctrv.2013.02.001</pub-id>
<?supplied-pmid 23453860?><pub-id pub-id-type="pmid">23453860</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffer</surname><given-names>E.</given-names></name><name><surname>Housset</surname><given-names>C.</given-names></name><name><surname>Cacheux</surname><given-names>W.</given-names></name><name><surname>Wendum</surname><given-names>D.</given-names></name><name><surname>Desbois-Mouthon</surname><given-names>C.</given-names></name><name><surname>Rey</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.</article-title>
<source><italic>Hepatology</italic></source>
<volume>41</volume>
<fpage>307</fpage>&#x02013;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1002/hep.20538</pub-id>
<?supplied-pmid 15660382?><pub-id pub-id-type="pmid">15660382</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>C.</given-names></name><name><surname>Bladt</surname><given-names>F.</given-names></name><name><surname>Goedecke</surname><given-names>S.</given-names></name><name><surname>Brinkmann</surname><given-names>V.</given-names></name><name><surname>Zschiesche</surname><given-names>W.</given-names></name><name><surname>Sharpe</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Scatter factor/hepatocyte growth factor is essential for liver development.</article-title>
<source><italic>Nature</italic></source>
<volume>373</volume>
<fpage>699</fpage>&#x02013;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1038/373699a0</pub-id>
<?supplied-pmid 7854452?><pub-id pub-id-type="pmid">7854452</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>L.</given-names></name><name><surname>Junker</surname><given-names>K.</given-names></name><name><surname>Nakaigawa</surname><given-names>N.</given-names></name><name><surname>Kinjerski</surname><given-names>T.</given-names></name><name><surname>Weirich</surname><given-names>G.</given-names></name><name><surname>Miller</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Novel mutations of the MET proto-oncogene in papillary renal carcinomas.</article-title>
<source><italic>Oncogene</italic></source>
<volume>18</volume>
<fpage>2343</fpage>&#x02013;<lpage>2350</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1202547</pub-id>
<?supplied-pmid 10327054?><pub-id pub-id-type="pmid">10327054</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semela</surname><given-names>D.</given-names></name><name><surname>Dufour</surname><given-names>J. F.</given-names></name></person-group> (<year>2004</year>). <article-title>Angiogenesis and hepatocellular carcinoma.</article-title>
<source><italic>J. Hepatol.</italic></source>
<volume>41</volume>
<fpage>864</fpage>&#x02013;<lpage>880</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2004.09.006</pub-id>
<?supplied-pmid 15519663?><pub-id pub-id-type="pmid">15519663</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>Y. Y.</given-names></name><name><surname>Hsu</surname><given-names>C. H.</given-names></name><name><surname>Cheng</surname><given-names>A. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: are we getting there?</article-title>
<source><italic>World J. Gastroenterol.</italic></source>
<volume>21</volume>
<fpage>10336</fpage>&#x02013;<lpage>10347</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v21.i36.10336</pub-id>
<?supplied-pmid 26420960?><pub-id pub-id-type="pmid">26420960</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorkin</surname><given-names>A.</given-names></name><name><surname>von Zastrow</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Endocytosis and signalling: intertwining molecular networks.</article-title>
<source><italic>Nat. Rev. Mol. Cell Biol.</italic></source>
<volume>10</volume>
<fpage>609</fpage>&#x02013;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2748</pub-id>
<?supplied-pmid 19696798?><pub-id pub-id-type="pmid">19696798</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinway</surname><given-names>S. N.</given-names></name><name><surname>Dang</surname><given-names>H.</given-names></name><name><surname>You</surname><given-names>H.</given-names></name><name><surname>Rountree</surname><given-names>C. B.</given-names></name><name><surname>Ding</surname><given-names>W.</given-names></name></person-group> (<year>2015</year>). <article-title>The EGFR/ErbB3 pathway acts as a compensatory survival mechanism upon c-Met inhibition in human c-Met+ hepatocellular carcinoma.</article-title>
<source><italic>PLoS One</italic></source>
<volume>10</volume>:<issue>e0128159</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0128159</pub-id>
<?supplied-pmid 26000702?><pub-id pub-id-type="pmid">26000702</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoker</surname><given-names>M.</given-names></name><name><surname>Gherardi</surname><given-names>E.</given-names></name><name><surname>Perryman</surname><given-names>M.</given-names></name><name><surname>Gray</surname><given-names>J.</given-names></name></person-group> (<year>1987</year>). <article-title>Scatter factor is a fibroblast-derived modulator of epithelial cell mobility.</article-title>
<source><italic>Nature</italic></source>
<volume>327</volume>
<fpage>239</fpage>&#x02013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1038/327239a0</pub-id>
<?supplied-pmid 2952888?><pub-id pub-id-type="pmid">2952888</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C. Y.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X. F.</given-names></name><name><surname>Tang</surname><given-names>L. P.</given-names></name><name><surname>Su</surname><given-names>Z. Q.</given-names></name><name><surname>Wang</surname><given-names>X. Q.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling.</article-title>
<source><italic>Oncotarget</italic></source>
<volume>8</volume>
<fpage>114945</fpage>&#x02013;<lpage>114955</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.22935</pub-id>
<?supplied-pmid 29383132?><pub-id pub-id-type="pmid">29383132</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Shiraha</surname><given-names>H.</given-names></name><name><surname>Fujikawa</surname><given-names>T.</given-names></name><name><surname>Takaoka</surname><given-names>N.</given-names></name><name><surname>Ueda</surname><given-names>N.</given-names></name><name><surname>Nakanishi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>280</volume>
<fpage>6409</fpage>&#x02013;<lpage>6415</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M406714200</pub-id>
<?supplied-pmid 15582995?><pub-id pub-id-type="pmid">15582995</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taher</surname><given-names>T. E.</given-names></name><name><surname>Derksen</surname><given-names>P. W.</given-names></name><name><surname>de Boer</surname><given-names>O. J.</given-names></name><name><surname>Spaargaren</surname><given-names>M.</given-names></name><name><surname>Teeling</surname><given-names>P.</given-names></name><name><surname>van der Wal</surname><given-names>A. C.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration.</article-title>
<source><italic>Biochem. Biophys. Res. Commun.</italic></source>
<volume>298</volume>
<fpage>80</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-291x(02)02397-2395</pub-id>
<?supplied-pmid 12379223?><pub-id pub-id-type="pmid">12379223</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takami</surname><given-names>T.</given-names></name><name><surname>Kaposi-Novak</surname><given-names>P.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Gomez-Quiroz</surname><given-names>L. E.</given-names></name><name><surname>Conner</surname><given-names>E. A.</given-names></name><name><surname>Factor</surname><given-names>V. M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis.</article-title>
<source><italic>Cancer Res.</italic></source>
<volume>67</volume>
<fpage>9844</fpage>&#x02013;<lpage>9851</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-07-1905</pub-id>
<?supplied-pmid 17942915?><pub-id pub-id-type="pmid">17942915</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Sasagawa</surname><given-names>S.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Trainor</surname><given-names>P. A.</given-names></name><name><surname>Cheng</surname><given-names>E. H.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>123</volume>
<fpage>3154</fpage>&#x02013;<lpage>3165</lpage>. <pub-id pub-id-type="doi">10.1172/jci65566</pub-id>
<?supplied-pmid 23934123?><pub-id pub-id-type="pmid">23934123</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeo</surname><given-names>S.</given-names></name><name><surname>Arai</surname><given-names>H.</given-names></name><name><surname>Kusano</surname><given-names>N.</given-names></name><name><surname>Harada</surname><given-names>T.</given-names></name><name><surname>Furuya</surname><given-names>T.</given-names></name><name><surname>Kawauchi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis.</article-title>
<source><italic>Cancer Genet. Cytogenet.</italic></source>
<volume>130</volume>
<fpage>127</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1016/s0165-4608(01)00479-474</pub-id>
<?supplied-pmid 11675133?><pub-id pub-id-type="pmid">11675133</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Ding</surname><given-names>K.</given-names></name><name><surname>Lobie</surname><given-names>P. E.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.</article-title>
<source><italic>FEBS Lett.</italic></source>
<volume>585</volume>
<fpage>2229</fpage>&#x02013;<lpage>2234</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2011.05.042</pub-id>
<?supplied-pmid 21658389?><pub-id pub-id-type="pmid">21658389</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>E.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Couchy</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant beta-catenin.</article-title>
<source><italic>Hepatology</italic></source>
<volume>64</volume>
<fpage>1587</fpage>&#x02013;<lpage>1605</lpage>. <pub-id pub-id-type="doi">10.1002/hep.28601</pub-id>
<?supplied-pmid 27097116?><pub-id pub-id-type="pmid">27097116</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavian</surname><given-names>D.</given-names></name><name><surname>De Petro</surname><given-names>G.</given-names></name><name><surname>Benetti</surname><given-names>A.</given-names></name><name><surname>Portolani</surname><given-names>N.</given-names></name><name><surname>Giulini</surname><given-names>S. M.</given-names></name><name><surname>Barlati</surname><given-names>S.</given-names></name></person-group> (<year>2000</year>). <article-title>u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma.</article-title>
<source><italic>Int. J. Cancer</italic></source>
<volume>87</volume>
<fpage>644</fpage>&#x02013;<lpage>649</lpage>. <?supplied-pmid 10925356?><pub-id pub-id-type="pmid">10925356</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueki</surname><given-names>T.</given-names></name><name><surname>Fujimoto</surname><given-names>J.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>H.</given-names></name><name><surname>Okamoto</surname><given-names>E.</given-names></name></person-group> (<year>1997</year>). <article-title>Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.</article-title>
<source><italic>Hepatology</italic></source>
<volume>25</volume>
<fpage>862</fpage>&#x02013;<lpage>866</lpage>. <pub-id pub-id-type="doi">10.1002/hep.510250413</pub-id>
<?supplied-pmid 9096589?><pub-id pub-id-type="pmid">9096589</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unic</surname><given-names>A.</given-names></name><name><surname>Derek</surname><given-names>L.</given-names></name><name><surname>Duvnjak</surname><given-names>M.</given-names></name><name><surname>Patrlj</surname><given-names>L.</given-names></name><name><surname>Rakic</surname><given-names>M.</given-names></name><name><surname>Kujundzic</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis.</article-title>
<source><italic>Ann. Clin. Biochem.</italic></source>
<volume>55</volume>
<fpage>355</fpage>&#x02013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1177/0004563217726808</pub-id>
<?supplied-pmid 28766361?><pub-id pub-id-type="pmid">28766361</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vejchapipat</surname><given-names>P.</given-names></name><name><surname>Tangkijvanich</surname><given-names>P.</given-names></name><name><surname>Theamboonlers</surname><given-names>A.</given-names></name><name><surname>Chongsrisawat</surname><given-names>V.</given-names></name><name><surname>Chittmittrapap</surname><given-names>S.</given-names></name><name><surname>Poovorawan</surname><given-names>Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma.</article-title>
<source><italic>J. Gastroenterol.</italic></source>
<volume>39</volume>
<fpage>1182</fpage>&#x02013;<lpage>1188</lpage>. <pub-id pub-id-type="doi">10.1007/s00535-004-1469-1468</pub-id>
<?supplied-pmid 15622483?><pub-id pub-id-type="pmid">15622483</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volinia</surname><given-names>S.</given-names></name><name><surname>Calin</surname><given-names>G. A.</given-names></name><name><surname>Liu</surname><given-names>C. G.</given-names></name><name><surname>Ambs</surname><given-names>S.</given-names></name><name><surname>Cimmino</surname><given-names>A.</given-names></name><name><surname>Petrocca</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>A microRNA expression signature of human solid tumors defines cancer gene targets.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>103</volume>
<fpage>2257</fpage>&#x02013;<lpage>2261</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0510565103</pub-id>
<?supplied-pmid 16461460?><pub-id pub-id-type="pmid">16461460</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Ferrell</surname><given-names>L. D.</given-names></name><name><surname>Faouzi</surname><given-names>S.</given-names></name><name><surname>Maher</surname><given-names>J. J.</given-names></name><name><surname>Bishop</surname><given-names>J. M.</given-names></name></person-group> (<year>2001</year>). <article-title>Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.</article-title>
<source><italic>J. Cell Biol.</italic></source>
<volume>153</volume>
<fpage>1023</fpage>&#x02013;<lpage>1034</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.153.5.1023</pub-id>
<?supplied-pmid 11381087?><pub-id pub-id-type="pmid">11381087</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S. W.</given-names></name><name><surname>Pan</surname><given-names>S. L.</given-names></name><name><surname>Peng</surname><given-names>C. Y.</given-names></name><name><surname>Huang</surname><given-names>D. Y.</given-names></name><name><surname>Tsai</surname><given-names>A. C.</given-names></name><name><surname>Chang</surname><given-names>Y. L.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression.</article-title>
<source><italic>Cancer Lett.</italic></source>
<volume>257</volume>
<fpage>87</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2007.07.002</pub-id>
<?supplied-pmid 17689859?><pub-id pub-id-type="pmid">17689859</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittaker</surname><given-names>S.</given-names></name><name><surname>Marais</surname><given-names>R.</given-names></name><name><surname>Zhu</surname><given-names>A. X.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of signaling pathways in the development and treatment of hepatocellular carcinoma.</article-title>
<source><italic>Oncogene</italic></source>
<volume>29</volume>
<fpage>4989</fpage>&#x02013;<lpage>5005</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2010.236</pub-id>
<?supplied-pmid 20639898?><pub-id pub-id-type="pmid">20639898</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>S.</given-names></name><name><surname>Carter</surname><given-names>C.</given-names></name><name><surname>Lynch</surname><given-names>M.</given-names></name><name><surname>Lowinger</surname><given-names>T.</given-names></name><name><surname>Dumas</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>R. A.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.</article-title>
<source><italic>Nat. Rev. Drug Discov.</italic></source>
<volume>5</volume>
<fpage>835</fpage>&#x02013;<lpage>844</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2130</pub-id>
<?supplied-pmid 17016424?><pub-id pub-id-type="pmid">17016424</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>R.</given-names></name><name><surname>Aspinall</surname><given-names>R.</given-names></name><name><surname>Bellis</surname><given-names>M.</given-names></name><name><surname>Camps-Walsh</surname><given-names>G.</given-names></name><name><surname>Cramp</surname><given-names>M.</given-names></name><name><surname>Dhawan</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis.</article-title>
<source><italic>Lancet</italic></source>
<volume>384</volume>
<fpage>1953</fpage>&#x02013;<lpage>1997</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(14)61838-61839</pub-id><pub-id pub-id-type="pmid">25433429</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Tao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.</article-title>
<source><italic>Hepatology</italic></source>
<volume>66</volume>
<fpage>1952</fpage>&#x02013;<lpage>1967</lpage>. <pub-id pub-id-type="doi">10.1002/hep.29374</pub-id>
<?supplied-pmid 28714063?><pub-id pub-id-type="pmid">28714063</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J. R.</given-names></name><name><surname>Hu</surname><given-names>C. T.</given-names></name><name><surname>You</surname><given-names>R. I.</given-names></name><name><surname>Pan</surname><given-names>S. M.</given-names></name><name><surname>Cheng</surname><given-names>C. C.</given-names></name><name><surname>Lee</surname><given-names>M. C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Hydrogen peroxide inducible clone-5 mediates reactive oxygen species signaling for hepatocellular carcinoma progression.</article-title>
<source><italic>Oncotarget</italic></source>
<volume>6</volume>
<fpage>32526</fpage>&#x02013;<lpage>32544</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.5322</pub-id>
<?supplied-pmid 26416447?><pub-id pub-id-type="pmid">26416447</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Q. F.</given-names></name><name><surname>Zhan</surname><given-names>M. X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>Y. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.</article-title>
<source><italic>Artif. Cells Nanomed. Biotechnol.</italic></source>
<volume>47</volume>
<fpage>83</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2018.1543195</pub-id>
<?supplied-pmid 30663411?><pub-id pub-id-type="pmid">30663411</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>B.</given-names></name><name><surname>Xing</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Gou</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference.</article-title>
<source><italic>J. Surg. Res.</italic></source>
<volume>162</volume>
<fpage>231</fpage>&#x02013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2009.04.030</pub-id>
<?supplied-pmid 19765730?><pub-id pub-id-type="pmid">19765730</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>K. D.</given-names></name><name><surname>Hu</surname><given-names>M. Y.</given-names></name><name><surname>Zhou</surname><given-names>K.</given-names></name></person-group> (<year>2001</year>). <article-title>SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma.</article-title>
<source><italic>World J. Gastroenterol.</italic></source>
<volume>7</volume>
<fpage>816</fpage>&#x02013;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v7.i6.816</pub-id>
<?supplied-pmid 11854908?><pub-id pub-id-type="pmid">11854908</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>R.</given-names></name><name><surname>Qin</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Exosomal miR-93 promotes proliferation and invasion in hepatocellular carcinoma by directly inhibiting TIMP2/TP53INP1/CDKN1A.</article-title>
<source><italic>Biochem. Biophys. Res. Commun.</italic></source>
<volume>502</volume>
<fpage>515</fpage>&#x02013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.05.208</pub-id>
<?supplied-pmid 29859935?><pub-id pub-id-type="pmid">29859935</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagamim</surname><given-names>H.</given-names></name><name><surname>Moriyama</surname><given-names>M.</given-names></name><name><surname>Matsumura</surname><given-names>H.</given-names></name><name><surname>Aoki</surname><given-names>H.</given-names></name><name><surname>Shimizu</surname><given-names>T.</given-names></name><name><surname>Saito</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases.</article-title>
<source><italic>Cancer</italic></source>
<volume>95</volume>
<fpage>824</fpage>&#x02013;<lpage>834</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.10732</pub-id>
<?supplied-pmid 12209727?><pub-id pub-id-type="pmid">12209727</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Shan</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>LINC00052/miR-101-3p axis inhibits cell proliferation and metastasis by targeting SOX9 in hepatocellular carcinoma.</article-title>
<source><italic>Gene</italic></source>
<volume>679</volume>
<fpage>138</fpage>&#x02013;<lpage>149</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2018.08.038</pub-id>
<?supplied-pmid 30098428?><pub-id pub-id-type="pmid">30098428</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>Y. Y.</given-names></name><name><surname>Zheng</surname><given-names>Z. Y.</given-names></name><name><surname>Fang</surname><given-names>J. H.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Vascular mimicry formation is promoted by paracrine TGF-beta and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma.</article-title>
<source><italic>Cancer Lett.</italic></source>
<volume>383</volume>
<fpage>18</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2016.09.012</pub-id>
<?supplied-pmid 27693460?><pub-id pub-id-type="pmid">27693460</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X. F.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Jia</surname><given-names>H. L.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>Q. Z.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.</article-title>
<source><italic>Hepatology</italic></source>
<volume>59</volume>
<fpage>1874</fpage>&#x02013;<lpage>1885</lpage>. <pub-id pub-id-type="doi">10.1002/hep.26941</pub-id>
<?supplied-pmid 24259426?><pub-id pub-id-type="pmid">24259426</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y. M.</given-names></name><name><surname>Lee</surname><given-names>C. G.</given-names></name><name><surname>Koo</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>T. H.</given-names></name><name><surname>Lee</surname><given-names>J. M.</given-names></name><name><surname>An</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Galpha12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4alpha inactivation, which causes c-Met induction.</article-title>
<source><italic>Oncotarget</italic></source>
<volume>6</volume>
<fpage>19055</fpage>&#x02013;<lpage>19069</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.3957</pub-id>
<?supplied-pmid 25965999?><pub-id pub-id-type="pmid">25965999</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yau</surname><given-names>T. C. C.</given-names></name><name><surname>Lencioni</surname><given-names>R.</given-names></name><name><surname>Sukeepaisarnjaroen</surname><given-names>W.</given-names></name><name><surname>Chao</surname><given-names>Y.</given-names></name><name><surname>Yen</surname><given-names>C. J.</given-names></name><name><surname>Lausoontornsiri</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>A Phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma.</article-title>
<source><italic>Clin. Cancer Res.</italic></source>
<volume>23</volume>
<fpage>2405</fpage>&#x02013;<lpage>2413</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-16-1789</pub-id>
<?supplied-pmid 27821605?><pub-id pub-id-type="pmid">27821605</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>H.</given-names></name><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>Dang</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Rountree</surname><given-names>C. B.</given-names></name></person-group> (<year>2011</year>). <article-title>c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.</article-title>
<source><italic>Hepatology</italic></source>
<volume>54</volume>
<fpage>879</fpage>&#x02013;<lpage>889</lpage>. <pub-id pub-id-type="doi">10.1002/hep.24450</pub-id>
<?supplied-pmid 21618573?><pub-id pub-id-type="pmid">21618573</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Liao</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Su</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Long noncoding RNA HULC promotes hepatocellular carcinoma progression.</article-title>
<source><italic>Aging</italic></source>
<volume>11</volume>
<fpage>9111</fpage>&#x02013;<lpage>9127</lpage>. <pub-id pub-id-type="doi">10.18632/aging.102378</pub-id>
<?supplied-pmid 31645479?><pub-id pub-id-type="pmid">31645479</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. P.</given-names></name><name><surname>Zeng</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Fang</surname><given-names>J. H.</given-names></name><name><surname>Zhuang</surname><given-names>S. M.</given-names></name></person-group> (<year>2014</year>). <article-title>MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling.</article-title>
<source><italic>Oncogene</italic></source>
<volume>33</volume>
<fpage>4069</fpage>&#x02013;<lpage>4076</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2013.369</pub-id>
<?supplied-pmid 24013226?><pub-id pub-id-type="pmid">24013226</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y. S.</given-names></name><name><surname>Chu</surname><given-names>J. H.</given-names></name><name><surname>Cui</surname><given-names>S. X.</given-names></name><name><surname>Song</surname><given-names>Z. Y.</given-names></name><name><surname>Qu</surname><given-names>X. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Des-gamma-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma.</article-title>
<source><italic>Cell Physiol. Biochem.</italic></source>
<volume>34</volume>
<fpage>903</fpage>&#x02013;<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1159/000366308</pub-id>
<?supplied-pmid 25200250?><pub-id pub-id-type="pmid">25200250</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2018a</year>). <article-title>LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma.</article-title>
<source><italic>J. Cell. Biochem.</italic></source>
<volume>119</volume>
<fpage>6045</fpage>&#x02013;<lpage>6056</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.26802</pub-id>
<?supplied-pmid 29574975?><pub-id pub-id-type="pmid">29574975</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S. Z.</given-names></name><name><surname>Pan</surname><given-names>F. Y.</given-names></name><name><surname>Xu</surname><given-names>J. F.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>S. Y.</given-names></name><name><surname>Dai</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo.</article-title>
<source><italic>Mol. Cancer Ther.</italic></source>
<volume>4</volume>
<fpage>1577</fpage>&#x02013;<lpage>1584</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.Mct-05-0106</pub-id>
<?supplied-pmid 16227408?><pub-id pub-id-type="pmid">16227408</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Kadel</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018b</year>). <article-title>The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma.</article-title>
<source><italic>J. Exp. Clin. Cancer Res.</italic></source>
<volume>37</volume>:<issue>93</issue>. <pub-id pub-id-type="doi">10.1186/s13046-018-0750-752</pub-id>
<?supplied-pmid 29712569?><pub-id pub-id-type="pmid">29712569</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>M.</given-names></name><name><surname>Jin</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Fan</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2018c</year>). <article-title>Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.</article-title>
<source><italic>Mol. Cancer</italic></source>
<volume>17</volume>:<issue>45</issue>. <pub-id pub-id-type="doi">10.1186/s12943-018-0796-y</pub-id>
<?supplied-pmid 29455668?><pub-id pub-id-type="pmid">29455668</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y. W.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Volpert</surname><given-names>O. V.</given-names></name><name><surname>Vande Woude</surname><given-names>G. F.</given-names></name></person-group> (<year>2003</year>). <article-title>Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>100</volume>
<fpage>12718</fpage>&#x02013;<lpage>12723</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2135113100</pub-id>
<?supplied-pmid 14555767?><pub-id pub-id-type="pmid">14555767</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>A. X.</given-names></name><name><surname>Kang</surname><given-names>Y. K.</given-names></name><name><surname>Yen</surname><given-names>C. J.</given-names></name><name><surname>Finn</surname><given-names>R. S.</given-names></name><name><surname>Galle</surname><given-names>P. R.</given-names></name><name><surname>Llovet</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.</article-title>
<source><italic>Lancet Oncol.</italic></source>
<volume>20</volume>
<fpage>282</fpage>&#x02013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(18)30937-30939</pub-id>
<?supplied-pmid 30665869?><pub-id pub-id-type="pmid">30665869</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>P. H.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Ruan</surname><given-names>L. T.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma.</article-title>
<source><italic>Oncol. Targets Ther.</italic></source>
<volume>10</volume>
<fpage>847</fpage>&#x02013;<lpage>857</lpage>. <pub-id pub-id-type="doi">10.2147/ott.S113353</pub-id>
<?supplied-pmid 28243120?><pub-id pub-id-type="pmid">28243120</pub-id></mixed-citation></ref></ref-list></back></article>